<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4931635</article-id><article-id pub-id-type="pmcid-ver">PMC4931635.1</article-id><article-id pub-id-type="pmcaid">4931635</article-id><article-id pub-id-type="pmcaiid">4931635</article-id><article-id pub-id-type="pmid">27258316</article-id><article-id pub-id-type="doi">10.3390/vaccines4020018</article-id><article-id pub-id-type="publisher-id">vaccines-04-00018</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Mitochondrion: A Promising Target for Nanoparticle-Based Vaccine Delivery Systems</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wen</surname><given-names initials="R">Ru</given-names></name><xref ref-type="aff" rid="af1-vaccines-04-00018">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Umeano</surname><given-names initials="AC">Afoma C.</given-names></name><xref ref-type="aff" rid="af1-vaccines-04-00018">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Francis</surname><given-names initials="L">Lily</given-names></name><xref ref-type="aff" rid="af1-vaccines-04-00018">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sharma</surname><given-names initials="N">Nivita</given-names></name><xref ref-type="aff" rid="af1-vaccines-04-00018">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tundup</surname><given-names initials="S">Smanla</given-names></name><xref ref-type="aff" rid="af2-vaccines-04-00018">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dhar</surname><given-names initials="S">Shanta</given-names></name><xref ref-type="aff" rid="af1-vaccines-04-00018">1</xref><xref rid="c1-vaccines-04-00018" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Harper</surname><given-names initials="DM">Diane M.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-04-00018"><label>1</label>NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA; <email>soso2012@uga.edu</email> (R.W.); <email>aumeano@uga.edu</email> (A.C.U.); <email>lgf39148@uga.edu</email> (L.F.); <email>nivita.sharma97@uga.edu</email> (N.S.)</aff><aff id="af2-vaccines-04-00018"><label>2</label>School of Medicine, Department of Pulmonary and Critical Care, University of Virginia, Charlottesville, WV 22908, USA; <email>st2vk@virginia.edu</email></aff><author-notes><corresp id="c1-vaccines-04-00018"><label>*</label>Correspondence: <email>shanta@uga.edu</email>; Tel.: +1-706-542-1012</corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2016</year></pub-date><volume>4</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">271996</issue-id><elocation-id>18</elocation-id><history><date date-type="received"><day>08</day><month>2</month><year>2016</year></date><date date-type="accepted"><day>08</day><month>4</month><year>2016</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>06</month><year>2016</year></date></event><event event-type="pmc-live"><date><day>08</day><month>07</month><year>2016</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-24 12:25:11.580"><day>24</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2016 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement><copyright-year>2016</copyright-year><license><license-p>This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-04-00018.pdf"/><abstract><p>Vaccination is one of the most popular technologies in disease prevention and eradication. It is promising to improve immunization efficiency by using vectors and/or adjuvant delivery systems. Nanoparticle (NP)-based delivery systems have attracted increasing interest due to enhancement of antigen uptake <italic toggle="yes">via</italic> prevention of vaccine degradation in the biological environment and the intrinsic immune-stimulatory properties of the materials. Mitochondria play paramount roles in cell life and death and are promising targets for vaccine delivery systems to effectively induce immune responses. In this review, we focus on NPs-based delivery systems with surfaces that can be manipulated by using mitochondria targeting moieties for intervention in health and disease.</p></abstract><kwd-group><kwd>vaccine</kwd><kwd>mitochondria targeting</kwd><kwd>nanoparticles</kwd><kwd>antigen delivery</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1-vaccines-04-00018"><title>1. Introduction</title><p>Vaccines are designed immunogenic antigens used to intentionally trigger the memory component of the immune system by stimulating humoral immunity <italic toggle="yes">via</italic> the production of antibodies for long term protection against various diseases [<xref rid="B1-vaccines-04-00018" ref-type="bibr">1</xref>] (<xref ref-type="fig" rid="vaccines-04-00018-f001">Figure 1</xref>). Attenuated or inactivated vaccine can elicit immunoprotection but duration of effect is limited and concerted to cellular immune responses [<xref rid="B2-vaccines-04-00018" ref-type="bibr">2</xref>]. Vectors and/or adjuvant delivery systems are widely used to augment immunogenicity of antigens, to protect vaccines from degradation in physiological environment, to improve efficacy of vaccines, and to target specific sites preventing unwanted accumulation [<xref rid="B3-vaccines-04-00018" ref-type="bibr">3</xref>].</p><p>For effective therapeutic use, vectors should be stable, biodegradable, biocompatible, easy to prepare, low cost, immunologically inert, and/or serve synergistically as an adjuvant. Nanoparticle (NP)-based payload cargos and adjuvants for vaccines are growing technologies due to their intrinsic immune-stimulatory properties, ability to co-entrap antigen adjuvants such as toll-like receptor (TLR) and enhancement of the antigen uptake by cells, e.g., by professional antigen presenting cell (APC) manipulation [<xref rid="B4-vaccines-04-00018" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-04-00018" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-04-00018" ref-type="bibr">6</xref>].</p><p>Mitochondria play essential roles for life and death processes of cells. This complex organelle participate in energy generation, intermediary metabolism, exchange of information, calcium signaling, and regulation of apoptosis [<xref rid="B7-vaccines-04-00018" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-04-00018" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-04-00018" ref-type="bibr">9</xref>]. Mitochondria-associated dysfunctions provide a predictable prospectus of defects in tissues for many ailments, spanning from subtle alterations causing symptomatic illness, to major functional defects leading to death [<xref rid="B10-vaccines-04-00018" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-04-00018" ref-type="bibr">11</xref>]. Mitochondria play an important role in the immune system, which involves signaling platforms, effector responses [<xref rid="B12-vaccines-04-00018" ref-type="bibr">12</xref>], and modulating the antigen-specific T cell activation <italic toggle="yes">via</italic> reactive oxygen species (ROS) signaling [<xref rid="B13-vaccines-04-00018" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-04-00018" ref-type="bibr">14</xref>]. Mitochondrial antigens, such as M2 autoantigens [<xref rid="B15-vaccines-04-00018" ref-type="bibr">15</xref>], oxo-acid dehydrogenase complexes [<xref rid="B16-vaccines-04-00018" ref-type="bibr">16</xref>] and 2-oxoglutarate dehydrogenase complex [<xref rid="B17-vaccines-04-00018" ref-type="bibr">17</xref>], are known to induce disease-related autoimmune responses such as primary biliary cirrhosis (PBC) [<xref rid="B15-vaccines-04-00018" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-04-00018" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-04-00018" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-04-00018" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-04-00018" ref-type="bibr">19</xref>]. The targets located in the different compartments of mitochondria for possible vaccine development are listed in <xref ref-type="table" rid="vaccines-04-00018-t001">Table 1</xref>. There are reports of mitochondria-targeted NP systems with the ability to produce tumor associated antigens (TAAs) that have the potential to act as preventive/therapeutic vaccines [<xref rid="B20-vaccines-04-00018" ref-type="bibr">20</xref>]. A mitochondria targeted vaccine was recently reported to stimulate the immune response by mitochondrial DNA (mtDNA) mutations upon immunization in a renal cancer murine model [<xref rid="B21-vaccines-04-00018" ref-type="bibr">21</xref>]. Such findings support previous studies performed by West <italic toggle="yes">et al.</italic> illustrating that mtDNA stress primes immune response [<xref rid="B22-vaccines-04-00018" ref-type="bibr">22</xref>], which may be critical to encourage effective immune stimulation, modulation, and memory-like protection in the context of vaccines. Therefore, mitochondria are promising targets for vaccine delivery systems to effectively induce immunity against diseases and to establish and/or boost therapeutic effects.</p><p>Although mitochondria can serve as important modulators for vaccines by serving as unique targets, the field of mitochondria targeted vaccines by using NP delivery system is still in infancy. This might be due to limited availability of NP systems for vaccine design. In this review, we highlight recent advances of antigen delivery carriers that can be manipulated to achieve mitochondria targeting and their potential interventions as preventive/therapeutic vaccines, by categorizing them into compositional classes of: (a) polymeric; (b) liposomal; and (c) other types of antigen carrier systems. Along with discussion of mitochondria targeting moieties, examples of mitochondria targeted NP vaccines are provided as well as future directions for this field.</p></sec><sec id="sec2-vaccines-04-00018"><title>2. NP-based Vaccine Delivery Systems</title><p>NP-based therapeutics are emerging as a noteworthy field in clinical research. Currently, there are several FDA approved cancer nanomedicines, such as Abraxane, Doxil, Oncaspar, <italic toggle="yes">etc.</italic> NPs provide an important tool for clinical application and, thus, should and can be evolved for systems that aim for various functions, such as in the case of vaccines. Adjuvant or antigen-targeting delivery systems are critical for efficient immune modulation by protecting antigens from extracellular enzymes and pH changes, and translocation of antigens to the target sites [<xref rid="B32-vaccines-04-00018" ref-type="bibr">32</xref>]. Here, we have categorized these NP-based vaccine delivery systems as polymeric, liposome, and others types of NP based carriers.</p><sec id="sec2dot1-vaccines-04-00018"><title>2.1. Polymeric NPs as Antigen Carriers</title><p>Antigens loaded into nanometer-sized polymeric particles were recently shown to produce good adjuvant effect [<xref rid="B33-vaccines-04-00018" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-04-00018" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-04-00018" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-04-00018" ref-type="bibr">36</xref>]. Polymeric NPs are used as adjuvants or antigen delivery cargos that can potentially be used in mitochondria-targeted vaccines. Polymeric NP are desirable platforms due to relative ease in tailoring (i) biodegradation properties and (ii) physical properties, such as size, surface charge, and hydrophobicity, for optimum cargo delivery/circulation and mitochondrial access. A list of polymeric NP based antigen delivery systems is summarized in <xref ref-type="table" rid="vaccines-04-00018-t002">Table 2</xref>.</p><p>Biodegradable NPs constructed from poly(lactic-co-glycolic acid) (PLGA) polymer are widely used as antigen carriers/adjuvants due to its biocompatible and biodegradable characteristics, with a safety profile approved by the US Food and Drug Administration (FDA) and European Medicine Agency (EMA) [<xref rid="B37-vaccines-04-00018" ref-type="bibr">37</xref>], good and controlled long-term release which results in strong immune response. Furthermore, PLGA NPs can carry a variety of antigens including gp120 and gp140 of the human immunodeficiency virus [<xref rid="B38-vaccines-04-00018" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-04-00018" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-04-00018" ref-type="bibr">40</xref>]. Not only were PLGA adjuvant NP systems reported to elicit a strong T cell immune response using 100-fold lower doses (0.05 &#181;g) of CpG oligodeoxynucleotide antigen, NP systems also showed significantly higher cytokine secretion (up to 10-fold), as well as a comparative antibody response to normal saline delivery [<xref rid="B41-vaccines-04-00018" ref-type="bibr">41</xref>].Thus, PLGA systems may be further developed for tailored vaccines towards increasing Th1 cell and innate immune response (e.g., viral hepatitis clearance).</p><p>There are considerable challenges that must be overcome in order to develop strong PLGA-based NP systems for vaccines. For one, PLGA-based NPs have poor payload loading and display accelerated burst release of vaccines to unwanted tissue or cells. Thus, several modifications have been done to overcome these issues. For examples, a pH sensitive PLGA NPs system was developed for rapid release of ovalbumin (OVA) antigen in acidic environments to improve immune response [<xref rid="B42-vaccines-04-00018" ref-type="bibr">42</xref>]. NPs were prepared by combination methods of emulsion-diffusion-extraction and emulsification and were ~890 nm in diameter with zeta potentials of ~ &#8722;12 mV. The antigen release profile was pH-dependent with over 85% release in acidic environments (pH 5.0 or 6.5) and low release (10%) at physiological pH for 24 h. <italic toggle="yes">In</italic>
<italic toggle="yes">vitro</italic> studies showed that PLGA-OVA NPs significantly enhanced CD86 and CD40 co-stimulatory factors, which induced higher level of cytokines IL-1<italic toggle="yes">&#946;</italic>, IL-6, IL-12p70 and TNF-&#945; than their control groups. <italic toggle="yes">In</italic>
<italic toggle="yes">vivo</italic> studies of PLGA-OVA NPs demonstrated enhanced activation of B cells, CD8<sup>+</sup> T cells, IgG titers, and Th1 polarization than their non-pH responsive control.</p><p>Delivery of dual or triple antigens in PLGA-NPs is also a possible strategy to enhance immune response efficiency. Co-delivery of TLR 4 ligand and TAA using PLGA-based NPs were reported to stimulate strong anti-tumor immune response [<xref rid="B43-vaccines-04-00018" ref-type="bibr">43</xref>]. This dual antigen loaded PLGA-based NP was prepared by double emulsion/solvent evaporation technique and vaccination of these NPs in healthy mice activated CD8<sup>+</sup> T cell immune responses with greater Th1 cytokines including IFN-<italic toggle="yes">&#947;</italic>, TNF-&#945;, and IL-2, -6, -12 production in both lymph nodes and spleen compared to 7-acyl lipid A NPs and empty-NP immunization. Polyethylene glycol (PEG) is a flexible, biocompatible, inert, amphiphilic, and non-toxic polymer that is FDA-approved for use in human. PEG is water soluble and, in NPs, prevents interactions between NPs and the cell surface environment. However, PEG-NP&#8217;s hydrophilic properties may lead to poor recognition and cellular uptake. NPs from other polymers such as poly(<sc>d</sc>,<sc>l</sc>-lactide) (PLA), poly (anhydride), poly(methyl methacrylate) (PMMA), poly(glycolic acid) (PGA), poly(<italic toggle="yes">&#949;</italic>-caprolactone) (PCL), chitosan, poly-L-lysine, poly(<italic toggle="yes">&#947;</italic>-glutamic acid) (PGA), can also serve as carriers for vaccine delivery.</p><p>Conjugation of two or more types of polymers by creating block copolymers, such as PLGA-<italic toggle="yes">b</italic>-PEG and PLA-<italic toggle="yes">b</italic>-PEG, are of particular interests as NPs carriers in vaccine development. Copolymers can be varied for ratios that to allow for the combined advantages of individual polymers and maximizes delivery and uptake efficiency. Factors including chain length of polymers, particle size, targeting moiety, and surface properties of NPs play significant roles in cellular uptake and immune efficacy of antigen. For example, Cruz <italic toggle="yes">et al.</italic> demonstrated significant effects of chain length of PEG and targeting moiety of antibody on the vaccine delivery and immune responses [<xref rid="B44-vaccines-04-00018" ref-type="bibr">44</xref>]. Chemically modified PLGA NPs were prepared by emulsification/solvent diffusion with various chain lengths of PEG <italic toggle="yes">via</italic> coupling to activated carboxyl groups. The NPs surface was coated with an antibody (hD1 or ZN-D1) identifying receptor for dendritic cells (DCs). The size of modified PLGA NPs increased with PEG chain length. The PLGA modified NPs with shorter chain length of PEG (MW: 2000&#8211;3000) and hD1 antibody showed higher uptake efficiency than longer PEG chain (MW: 6000&#8211;20000) modified larger NPs either with or without hD1 antibody. PLGA modified NPs coated with hD1 or AZN-D1 were more efficient for cellular uptake and targeting than those coated with H200, neck motif receptor. These results indicated that chain length of PEG and antibody types influence the ligand-receptor targeting by tailoring the size and surface properties of NPs. Plasmid DNA was loaded into PLGA-polyethyleneimine (PEI) NPs with positive surface charge of 40&#8211;70 mV and size of 230&#8211;280 nm by precipitation-evaporation-filtration method [<xref rid="B45-vaccines-04-00018" ref-type="bibr">45</xref>]. <italic toggle="yes">In vitro</italic> studies showed that PLGA-PEI-DNA NPs could stimulate human DCs to secrete IL-12 and TNF-&#945;. <italic toggle="yes">In vivo</italic> study demonstrated enhanced T cell proliferation by immunization with PLGA-PEI-DNA NPs.</p><p>Biopolymers, like chitosan, can also be used to prepare comparably cost-effective NPs as stable carriers for antigens to trigger immune response for diseases, such as Hepatitis B, Tetanus, and Leishamaniasis [<xref rid="B46-vaccines-04-00018" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-04-00018" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-04-00018" ref-type="bibr">48</xref>]. For example, chitosan NPs prepared by ionic gelation were developed to successfully deliver TLR3 agonist poly (I:C) (pIC) and a T-Helper peptide (PADRE) to produce antibody against disease [<xref rid="B49-vaccines-04-00018" ref-type="bibr">49</xref>]. <italic toggle="yes">In vivo</italic> studies in mice indicated that both immunostimulant pIC and T helper peptide were critical to reach valuable immune responses upon immunization with chitosan NPs. The present condition of antigen in the NPs was an important factor for immune responses, whereas the adsorption of peptide on the surface of NPs showed higher antibody response than the entrapping counterpart.</p></sec><sec id="sec2dot2-vaccines-04-00018"><title>2.2. Liposomal Systems as Antigen Carrier/Adjuvant</title><p>Liposomes are effective antigen carriers due to biodegradable, nontoxic, non-immunogenic, and antigen loading properties. These systems are reported to deliver a wide range of antigens, such as E7 peptide and HSP70, which can potentially vaccinate against many disease, such as cancer and human papilloma virus [<xref rid="B14-vaccines-04-00018" ref-type="bibr">14</xref>,<xref rid="B60-vaccines-04-00018" ref-type="bibr">60</xref>]. <xref ref-type="table" rid="vaccines-04-00018-t003">Table 3</xref> summarizes the liposome-based NPs in vaccine delivery systems. Lipids, such as dioleoyl phosphatidyl ethanolamine (DOPE), dioleoyl phosphatidylcholine (DOPC) cholesterol, dioleoyldimethylammonium chloride (DODAC), dioleoyldimethylaminopropane (DOTAP), dipalmitoylphospatidylcholine (DPPC), dipalmitoylphospatidylglycerol (DPPG), can be used to prepare liposome-based NP delivery systems for vaccines. The endosomolytic lipid DOPE can enhance the efficacy of vaccine delivery by endosomal escape through membrane disruption and fusion processes [<xref rid="B61-vaccines-04-00018" ref-type="bibr">61</xref>]. For instance, Cui <italic toggle="yes">et al.</italic> [<xref rid="B62-vaccines-04-00018" ref-type="bibr">62</xref>] reported DOPE as lipid source for preparation of liposome-based adjuvant NPs as plasmid DNA (pDNA) vaccine carriers. The pDNA-lipid adjuvant NPs had a 250-fold enhanced activity than pDNA alone for <italic toggle="yes">in vivo</italic> immunization in BALB/c mice model.</p><p>Liposomal NPs are potentially able to cross epithelial barriers and protect encapsulated antigens from enzymatic attack in physiological environment [<xref rid="B63-vaccines-04-00018" ref-type="bibr">63</xref>]. Oral route delivery of vaccine is one of the most challenging and difficult tasks in vaccine development. Towards the development of oral or nasal vaccines, liposomal NPs can undergo reverse denaturation, surviving GI tract and other enzyme-rich environments. However, liposomal NPs are unstable and rapidly cleared by the mononuclear phagocyte system (MPS). The combination of liposome and polymer is a possible strategy for construction of antigen nanovesicles to resolve deficiencies in uptake efficacy and immune response enhancement. Many types of combination nanocarriers, such as liposome-chitosan NPs [<xref rid="B64-vaccines-04-00018" ref-type="bibr">64</xref>], were reported for drug-delivery and such systems may be further evolved for antigen delivery as well. Polymerized liposomes, which can be prepared under mild conditions comparable to conventional liposomes, exhibit greater encapsulation efficiency, better activity of antigen, and more controllable antigen release profile than conventional liposomes. The solid and stable structure of polymerized liposomes with easy preparation method make these NPs a promising antigen delivery vesicle [<xref rid="B65-vaccines-04-00018" ref-type="bibr">65</xref>]. Polymerized liposomes showed their potential as oral vaccine delivery system [<xref rid="B66-vaccines-04-00018" ref-type="bibr">66</xref>], however, further studies are required for clinical application.</p><p>Solid Lipid NPs (SLNPs) with a diameter of 50&#8211;1000 nm can be prepared by replacing the liquid lipid by various types of solid lipids, such as fatty acids, triglycerides, and their combinations [<xref rid="B67-vaccines-04-00018" ref-type="bibr">67</xref>]. The uptake efficiency and immunogenicity of antigen loaded SLNPs can be affected by size, lipid source, preparation method, and surface properties. For example, Bhargava <italic toggle="yes">et al.</italic> reported SLNPs as tumor antigen carriers, which demonstrated immune signal induction with no toxicity [<xref rid="B68-vaccines-04-00018" ref-type="bibr">68</xref>]. With tumor lysate as antigen, SLNPs were synthesized by solvent injection method with tristearin as a lipid source. SLNPs size was controlled by varying preparation parameters. The monomannosyl&#8211;dioleyl glycerol modified SLNPs showed the highest uptake efficiency and immune response among other lipid modified controls, which may be attributed to efficient antigen capture by mannose receptors of DCs.</p><p>The efficacious delivery and safety profile of liposome-based NP systems make them as promising vehicles for vaccine delivery. The immune-stimulant sipuleucel-T received FDA approval for asymptomatic or minimally symptomatic prostate cancer in 2010 and is used to prime metastatic prostate cancer patient&#8217;s T-cells to target the patient&#8217;s own cancer cells. Liposomes formulated prostate-specific antigen (PSA) is reported to generate immune response when injected into patients (65&#8211;80 years old) with prostate cancer. Out of 10, 8 patients showed PSA-reactive T-cell frequencies using <italic toggle="yes">in vitro</italic> sensitization method. The vaccination trial indicated that the patients survived within 22&#8211;33 months with one still alive during the testing timeline, whereas eight patients were stable and the rest of them deteriorated to progressive disease [<xref rid="B69-vaccines-04-00018" ref-type="bibr">69</xref>]. Another pilot study demonstrated the safety profile of MUC1 BLP25 liposomal vaccine. L-BLP25 was prepared by encapsulating BLP25 lipopeptide to form liposomal adjuvant with monophosphoryl lipid A and 3 lipids (cholesterol, dimyristoyl phosphatidylglycerol and dipalmitoyl phosphatidylcholine). Twenty patients (&#8805;18-year-old) were continuously vaccinated with BLP25 liposome vaccine after single dose of cyclophosphamide for up to 1 year. No autoimmunity was observed, indicating that L-BLP25 vaccine is safe for therapeutic use [<xref rid="B70-vaccines-04-00018" ref-type="bibr">70</xref>]. A recent internationally randomized and double-blind phase III clinical trial composed of 1513 patients with non-small-cell unresectable stage III lung cancer, tested L-BLP25 as an immunotherapeutic [<xref rid="B71-vaccines-04-00018" ref-type="bibr">71</xref>]. The overall survival was 25.6 months for patients vaccinated with L-BLP25 compared to 22.3 months for patients treated with placebo. These results indicate the potential clinical benefit of L-BLP25 for cancer immunotherapy and warrant further studies [<xref rid="B71-vaccines-04-00018" ref-type="bibr">71</xref>].</p></sec><sec id="sec2dot3-vaccines-04-00018"><title>2.3. Others Types of NP-based Systems as Antigen Carrier/Adjuvant</title><p>There are reports on other NP carriers for the delivery of vaccines other than polymeric or liposome-based NPs. For instance, inorganic NPs are suitable antigen delivery systems due to wide availability, rich functionality, and good biocompatibility. Many inorganic materials, such as aluminum salt, silver, gold, carbon materials, silicon oxide, and iron oxide were studied for use as antigen delivery carriers. <xref ref-type="table" rid="vaccines-04-00018-t004">Table 4</xref> summarizes these NP carriers for antigen delivery. For example, Villa <italic toggle="yes">et al.</italic> [<xref rid="B72-vaccines-04-00018" ref-type="bibr">72</xref>] reported single-wall carbon nanotubes (SWNTs) as human tumor antigens carriers to improve immune responses. SWNT-peptide delivery systems were constructed using weakly immunogenic cancer-associated peptide WT1-Pep427 consisting of 19 amino acids. The SWNT-peptide delivery systems showed enhanced <italic toggle="yes">in vivo</italic> immune responses in mice model. More importantly, SWNTs alone did not show any toxicity or immunogenicity <italic toggle="yes">in vitro</italic> or <italic toggle="yes">in vivo</italic>, and no immunogenic responses were reported for this SWNT construct.</p><p>Layered double hydroxides NPs (LDH-NPs) are considered as potential vaccine nanocarriers due to good biocompatibility, low toxicity, great antigen protective and controllable release properties. LDH-NPs are hydrotalcite-like anionic clays with a common formula as [M<sup>2+</sup><sub>1&#8722;x</sub>M<sup>3+</sup><sub>x</sub>(OH)<sub>2</sub>]<sup>x+</sup>(A<sup>n&#8722;</sup>)<sub>x/n</sub>&#183;yH<sub>2</sub>O, where M is a metal cation (e.g., Mg<sup>2+</sup>, Al<sup>3+</sup>) located at octahedral sites and A is a inorganic anion (e.g., Cl<sup>&#8722;</sup>, CO<sub>3</sub><sup>2&#8722;</sup>) situated at interlayers [<xref rid="B73-vaccines-04-00018" ref-type="bibr">73</xref>]. LDH-NPs provides efficient uptake of antigens due to their high endosomal buffering capacity and controllable released profiles [<xref rid="B74-vaccines-04-00018" ref-type="bibr">74</xref>]. Yan <italic toggle="yes">et al.</italic> demonstrated that OVA loaded LDH-NPs (~100 nm in diameter) prepared by a combination of precipitation and hydrothermal methods exhibited less inflammation but comparable adjuvanticity to induce Th1/Th2 immune response [<xref rid="B75-vaccines-04-00018" ref-type="bibr">75</xref>]. Modification of OVA-LDH-NPs by CpG receptor ligand significantly enhanced immune response. <italic toggle="yes">In vivo</italic> studies showed that LDH-CpG-OVA NP injections had six-fold of IgG2a/IgG1 ratio and less inflammatory activity than mice treated with Alum-CpG-OVA. Hybrid of different types of NPs to combine the advantages of individual NPs is an effective strategy to enhance vaccine immune response. This hybrid strategy is widely used in drug delivery, and can also be applied to vaccine developments. For example Wang <italic toggle="yes">et al.</italic> reported SiO<sub>2</sub>@LDH NPs as adjuvant for DNA vaccination to improve immune response for hepatitis B [<xref rid="B76-vaccines-04-00018" ref-type="bibr">76</xref>]. Core-shell SiO<sub>2</sub>@LDH (~210 nm in diameter) NPs showed adjuvant activity for maturation of DC <italic toggle="yes">in vitro</italic> and enhanced immune responses with greater generation of IFN-<italic toggle="yes">&#947;</italic>, IL-6, MHCII, and CD86 <italic toggle="yes">in vivo</italic>. However, toxicity of LDH NPs needs to be addressed for clinical applications.</p></sec></sec><sec id="sec3-vaccines-04-00018"><title>3. Mitochondria Targeting Moiety</title><p>As mentioned previously, mitochondria have unique immunostimulatory capabilities that can enhance vaccine activity. Mitochondria targeting can be achieved by selectively conjugating the polymer or modifying the particle surface with a mitochondria targeting moiety. The unique properties of the mitochondrion, such as the existence of a mitochondrial membrane potential (&#916;<italic toggle="yes">&#968;</italic><sub>m</sub>) across a mitochondrion&#8217;s double membrane, and the mitochondrial protein import machinery indicates that lipophilic cations and specific mitochondrial targeting sequences (MTS) can be used to achieve effective mitochondria targeting.</p><p>(i) Lipophilic cation: One approach to confer mitochondria targeting properties to a vaccine is through conjugation to a delocalized lipophilic cation, such as triphenylphosphonium (TPP) cation [<xref rid="B28-vaccines-04-00018" ref-type="bibr">28</xref>,<xref rid="B56-vaccines-04-00018" ref-type="bibr">56</xref>,<xref rid="B117-vaccines-04-00018" ref-type="bibr">117</xref>], rhodamine 123 [<xref rid="B118-vaccines-04-00018" ref-type="bibr">118</xref>], or methyltriphenylphosphonium (TPMP) cation [<xref rid="B119-vaccines-04-00018" ref-type="bibr">119</xref>]. Lipophilic cations access the mitochondrion through a driving force caused by the &#916;<italic toggle="yes">&#968;</italic><sub>m</sub> gradient [<xref rid="B120-vaccines-04-00018" ref-type="bibr">120</xref>]. Cancer cells display a hyperpolarized &#916;<italic toggle="yes">&#968;</italic><sub>m</sub> across membranes in their mitochondrial population, which facilitate the accumulation of lipophilic cations. Thus, lipophilic cation conjugated NPs can be used as carriers to target the antigens to mitochondria. A summary of mitochondria targeting moieties is shown in <xref ref-type="table" rid="vaccines-04-00018-t005">Table 5</xref>.</p><p>TPP is a commonly used cation for mitochondria targeting due to its characteristic facile conjugation and efficient rapid uptake into mitochondrion. Nevertheless, the toxicity of TPP-based small organic molecules limits its use in therapeutic applications. Conjugation of TPP cations into a stable polymer, lipid or other nanomaterials can solve this problem. TPP derived polymers used as mitochondria targeting moiety for polymer surface manipulation as delivery systems exhibited less toxicity in recent studies. We recently reported a biocompatible polymeric NP for mitochondria targeting, where biodegradable PLGA-<italic toggle="yes">b</italic>-PEG was functionalized with a terminal TPP cation, forming PLGA-PEG-TPP [<xref rid="B56-vaccines-04-00018" ref-type="bibr">56</xref>,<xref rid="B131-vaccines-04-00018" ref-type="bibr">131</xref>]. This polymer has the advantages of being non-toxic, easy to prepare, and stable. Furthermore, it demonstrated success in efficient mitochondria associated delivery of different small molecules which included Pt(IV) compounds [<xref rid="B132-vaccines-04-00018" ref-type="bibr">132</xref>,<xref rid="B133-vaccines-04-00018" ref-type="bibr">133</xref>,<xref rid="B134-vaccines-04-00018" ref-type="bibr">134</xref>], ZnPc [<xref rid="B21-vaccines-04-00018" ref-type="bibr">21</xref>,<xref rid="B27-vaccines-04-00018" ref-type="bibr">27</xref>], aspirin [<xref rid="B135-vaccines-04-00018" ref-type="bibr">135</xref>]. Tagging to other nanomaterials with TPP cation is widely used and achieved by our group. For instance, gold nanoparticle (AuNP) to 3-bromopyruvate, high density lipoproteins [<xref rid="B136-vaccines-04-00018" ref-type="bibr">136</xref>,<xref rid="B137-vaccines-04-00018" ref-type="bibr">137</xref>], and all display no differences between controls and TPP conjugated NPs in toxicity and immunogenicity evaluations. Hence, these TPP-modified NP systems are promising for antigen delivery to mitochondria as well.</p><p>(ii) Mitochondria targeting sequence (MTS): Mitochondrial proteins are encoded by nuclear gene and further synthesized by cytoplasmic free ribosomes [<xref rid="B138-vaccines-04-00018" ref-type="bibr">138</xref>]. The translocation and intracellular sorting of these proteins to mitochondrial compartments depend on MTS [<xref rid="B139-vaccines-04-00018" ref-type="bibr">139</xref>]. Thus, MTS can be used as the targeting moiety. MTS commonly have a length of 20-40 amino acids and are located at the amino terminal of the precursor proteins. MTS form amphiphilic &#945;-helical conformations with cationic amino acids on one side and hydrophobic amino acid on the opposing surface [<xref rid="B140-vaccines-04-00018" ref-type="bibr">140</xref>,<xref rid="B141-vaccines-04-00018" ref-type="bibr">141</xref>,<xref rid="B142-vaccines-04-00018" ref-type="bibr">142</xref>]. <xref ref-type="table" rid="vaccines-04-00018-t006">Table 6</xref> summarizes MTS as mitochondria targeting ligands and their targets in the protein import machinery pathway.</p></sec><sec id="sec4-vaccines-04-00018"><title>4. Examples of Targeted NP-Based Vaccine</title><p>To demonstrate how mitochondria targeting NP-based vaccines can be developed, here we will provide possible modifications for immune modulation and vaccine development.</p><p>T lymphocytes with CD4 and CD8 surface proteins are referred to as CD4<sup>+</sup> and CD8<sup>+</sup> T cells, respectively. CD8<sup>+</sup> T cells are cytotoxic when activated within the immune system, whereas CD4<sup>+</sup> T cells are helpers in activating CD8<sup>+</sup> T cells or humoral immune responses [<xref rid="B161-vaccines-04-00018" ref-type="bibr">161</xref>]. The activation of CD8<sup>+</sup> T cells requires the presence of APCs. DCs, the most effective APCs, present antigens to B and T lymphocytes for initiating antigen-specific immune responses or immunological tolerance through antigen and costimulatory molecules [<xref rid="B162-vaccines-04-00018" ref-type="bibr">162</xref>,<xref rid="B163-vaccines-04-00018" ref-type="bibr">163</xref>]. T-cell antigen receptors recognize antigens by binding APC surface major histocompatibility complex (MHC) molecules, whereas CD8<sup>+</sup> T cells are activated by DCs [<xref rid="B164-vaccines-04-00018" ref-type="bibr">164</xref>,<xref rid="B165-vaccines-04-00018" ref-type="bibr">165</xref>]. Thus, DCs are attractive for therapeutics that rely on immune mediation, such as vaccines, and can be used to target infection, cancer, and tumor immunity [<xref rid="B165-vaccines-04-00018" ref-type="bibr">165</xref>,<xref rid="B166-vaccines-04-00018" ref-type="bibr">166</xref>,<xref rid="B167-vaccines-04-00018" ref-type="bibr">167</xref>].</p><p>DCs play an important in role in shaping adaptive immune responses. When activated, immature DCs express increased levels of co-stimulatory molecules, consequently leading to potent adaptive immune response [<xref rid="B168-vaccines-04-00018" ref-type="bibr">168</xref>]. Activation of DCs occurs in response to inflammatory chemokines, such as MCP1, MI-3&#945;. DCs are recruited to the inflammation site, where they mature into functional DCs to regulate antigen capturing, processing, and expression of co-stimulatory molecules for activating T cells [<xref rid="B165-vaccines-04-00018" ref-type="bibr">165</xref>,<xref rid="B169-vaccines-04-00018" ref-type="bibr">169</xref>,<xref rid="B170-vaccines-04-00018" ref-type="bibr">170</xref>]. Because DCs are the primary APCs and their activation and maturation is crucial in shaping an effective T-cell response against invading pathogens or cancer cells, approaches aimed to increase uptake, activation and efficiency in antigen presentation should improve vaccine efficacy. In this way, NP-based antigen delivery systems can be used to drive immature DCs towards maturation for immune response activation against a delivered antigen. </p><p>Chong <italic toggle="yes">et al.</italic> [<xref rid="B38-vaccines-04-00018" ref-type="bibr">38</xref>] reported PLGA NPs for co-delivery of hepatitis B core antigen (HBcAg) and monophospholipid A (MPLA), a ligand for TLR, as therapeutic vaccines. A PLGA NP system was used to deliver antigen and Th1 promoting adjuvant to DCs to enhance immune response. The study demonstrated a synergistic effect, in regards to the PLGA NP co-delivery system, with anti-HBcAg IgG detection in sera and robust T cell proliferation response in mice <italic toggle="yes">via</italic> a booster dose. IFN-<italic toggle="yes">&#947;</italic> produced by T cells from the spleen and lymph nodes were 4- and 6-fold enhanced in mice immunized with HBcAg + MPLA-NPs than HBcAg NPs, respectively. Furthermore, no IL-4, a cytokine associated with cytotoxic immune response dampening, was found. Pulsing synthetic tumor peptides to DCs was demonstrated to elicit protective and therapeutic antitumor immunity [<xref rid="B171-vaccines-04-00018" ref-type="bibr">171</xref>]. A mitochondria targeting NP vaccine can be achieved by modifying this PLGA-NP carrier with a mitochondria targeting ligand, such as TPP.</p><p>A mechanism in which a vaccine can confer immune protection against disease using APCs is through triggering the selective or abundant expression or release of internal antigen in dysfunctional cells. Apoptotic cells, tumor lysates, and TAAs are all types of internal antigens that can be recognized by APCs. Rahma <italic toggle="yes">et al.</italic> [<xref rid="B172-vaccines-04-00018" ref-type="bibr">172</xref>] reported that pre-immature DCs pulsed with HPV16 E6 or E7 peptide derived from early genes E6 and E7 in high-risk HPV types 16 and 18 were well tolerated and able to induce specific immune responses in patients for therapeutic cervical cancer. Other vaccines are being developed against TAAs for vaccination of patients with various cancers. Rong <italic toggle="yes">et al.</italic> [<xref rid="B173-vaccines-04-00018" ref-type="bibr">173</xref>] developed a DC-based vaccine using MUC1-peptide, a TAA associated with late stage pancreatic cancer. In preliminary studies, IFN-<italic toggle="yes">&#947;</italic> and granzyme B, markers for cytotoxic immune response, were significantly enhanced in some patients. Phuphanich <italic toggle="yes">et al.</italic> [<xref rid="B174-vaccines-04-00018" ref-type="bibr">174</xref>] demonstrated the feasibility, safety, and bioactivity of TAA peptide for autologous vaccines by pulsing a class 1 peptide TAA expressed in patient&#8217;s glioma onto DCs. The TAA peptide pulsed DC vaccine administered intradermally into patients was nontoxic and led to elimination of CD133<sup>+</sup> recurrent tumors cells. It is possible to target mitochondria of dysfunctional cells using NP-based system to trigger increased expression of internal antigens, especially TAAs, by inducing apoptosis (and generating apoptotic cells) for APC recognition and vaccines.</p><p>Antigen simulating activity by adjuvant has potential for synergistic effects resulting in stronger immune responses compared to antigen or delivery system alone. Tamayo <italic toggle="yes">et al.</italic> [<xref rid="B175-vaccines-04-00018" ref-type="bibr">175</xref>] reported a poly(anhydride) NP system for Th1 adjuvant immunoprophylaxis and immunotherapy. Studies demonstrated that poly(anhydride) NPs can act as agonists of various TLRs (e.g., TLR2, -4, and -5), to induce Th1-cytokine production (IFN-<italic toggle="yes">&#947;</italic>, IL-12) and trigger the expression of CD54 and CD86 co-stimulatory molecules after incubation with DCs. The <italic toggle="yes">in vivo</italic> studies suggested that NPs help elicit CD8<sup>+</sup> T cell response. The co-administration of empty NPs with OVA showed induction of cytotoxic T cells specific for target cells. Furthermore, IFN-<italic toggle="yes">&#947;</italic> was detected in splenocytes from mice immunized with NPs and OVA. Aluminum-based adjuvants are licensed in vaccine with long record of safety without side effects of immune complex disorders [<xref rid="B176-vaccines-04-00018" ref-type="bibr">176</xref>]. &#945;-Al<sub>2</sub>O<sub>3</sub> NPs is reported to be a promising adjuvant in therapeutic cancer vaccines [<xref rid="B177-vaccines-04-00018" ref-type="bibr">177</xref>]. <italic toggle="yes">In vitro</italic> and <italic toggle="yes">in vivo</italic> studies demonstrated that the required antigen necessary to activate T cells was reduced by using &#945;-Al<sub>2</sub>O<sub>3</sub> NP adjuvant system. Notably, tumor growth was inhibited for more than 40 days and high levels of OVA-specific T cells were detected in mice immunized by &#945;-Al<sub>2</sub>O<sub>3</sub>-OVA NPs.</p><p>Photodynamic therapy (PDT) is a rapidly developing tactic for therapeutic vaccines. It has the advantage of accurately locating photosensitizer (PS) to the desired sites by light irradiation [<xref rid="B178-vaccines-04-00018" ref-type="bibr">178</xref>]. PS molecule can be excited to produce reactive oxygen species (ROS) [<xref rid="B179-vaccines-04-00018" ref-type="bibr">179</xref>,<xref rid="B180-vaccines-04-00018" ref-type="bibr">180</xref>]. The increase in ROS results in tumor cell apoptosis and stimulates the host&#8217;s immune response. A combination of PDT with mitochondria targeted NP is a possible strategy to stimulate the immune system. Our group [<xref rid="B21-vaccines-04-00018" ref-type="bibr">21</xref>] reported mitochondria targeted NPs containing ZnPc and combined with PDT to <italic toggle="yes">ex vivo</italic> stimulate DCs to secrete the cytokines, especially IFN-<italic toggle="yes">&#947;</italic> and DC mediated activation of CD8<sup>+</sup> T cells by procuring antigens from MCF-7 breast cancer cells (<xref ref-type="fig" rid="vaccines-04-00018-f002">Figure 2</xref>). The mitochondria-targeted polymer PLGA-<italic toggle="yes">b</italic>-PEG-TPP was employed as ZnPc delivery cargo with TPP cation as mitochondria targeting moiety. The targeted ZnPc NPs showed enhanced apoptotic properties compared to non-targeted NPs by triggering mitochondria-mediated apoptosis. The TAAs from apoptotic cancer cells were then released and internalized by DCs, which further led to the CD8<sup>+</sup> T cell activation. Cytokines IL-18 and IFN-&#947; were secreted by bone marrow derived DCs stimulated by apoptotic cancer cells produced by mitochondria targeted ZnPc NP treatment in the presence of light.</p><p>These results indicated that mitochondria-targeted-NP delivery systems containing mitochondria-acting photosensitizers are suitable for activating tumor cells which can further activate DCs for subsequent immune response. Our group also reported the combination of ZnPc and CpG-ODN in PLGA-<italic toggle="yes">b</italic>-PEG polymer carrier, which resulted in significant phototoxicity of 4T1 metastatic mouse breast carcinoma cells [<xref rid="B28-vaccines-04-00018" ref-type="bibr">28</xref>]. The PLGA-<italic toggle="yes">b</italic>-PEG-NP system was modified with CpG-ODN-coated gold NPs on the surface. The CpG-ODN&#8211;Au&#8211;ZnPc&#8211;Poly-NPs were highly toxic to 4T1 cells under irradiation [<xref rid="B28-vaccines-04-00018" ref-type="bibr">28</xref>]. These results suggest that patients with light accessible cancers may be treated by administration of a PDT active mitochondrial targeting vaccine NP systems that capitalize on optimizing immune function for cancer cell death and prevention, overall preventing the need for harsh chemotherapeutics and decreasing the rate of recurrence <italic toggle="yes">via</italic> lingering immune surveillance by memory cells.</p><p>Besides DCs, microfold cells (M cells), specific epithelial cells of mucosa-related lymphoid tissues that transport antigens from the lumen to immune cells, and macrophages can also initiate immune response and/or tolerance. Thus, it is possible to target mitochondria of macrophages and/or M cells with mitochondria-targeted NPs for therapeutic vaccine [<xref rid="B181-vaccines-04-00018" ref-type="bibr">181</xref>]. Fievez <italic toggle="yes">et al.</italic> [<xref rid="B182-vaccines-04-00018" ref-type="bibr">182</xref>] reported NPs with non-peptide ligands for targeting M cells for oral vaccination. The targeted OVA NPs showed enhanced cellular immune response with high levels of IFN-<italic toggle="yes">&#947;</italic> production and consistently low levels of IL-4 in splenocytes. <italic toggle="yes">In vivo</italic> studies in mice indicated higher IgG immune response than non-targeted formulations. Chen <italic toggle="yes">et al.</italic> [<xref rid="B183-vaccines-04-00018" ref-type="bibr">183</xref>] reported liposomal NPs as antigen delivery systems for macrophages. By decorating liposomes with 3&#8217;-BPCNeuAc ligands and glycan ligand, delivery of the antigens to endosomes and lysosomes, respectively, were achieved. Results demonstrated that liposomal NPs were efficient in delivering OVA to bone marrow derived macrophages and significantly enhanced T cell proliferation. By modifying the liposome with mitochondria targeting moiety, it will be possible to target the antigen NPs into mitochondria for efficient antigen delivery and immune response. Zhou <italic toggle="yes">et al.</italic> [<xref rid="B184-vaccines-04-00018" ref-type="bibr">184</xref>] reported that graphene nanosheets of diameter 172.7&#177;75.6 nm and of thickness 2&#8211;3 nm induced the secretion of Th1/Th2 cytokines (IL-1&#945;, IL-6, IL-10, TNF-&#945;) and chemokines (GM-CSF MCP-1, MIP-1&#945;, MIP-1&#946;, RANTES) in murine macrophages. These settings of NPs can be potentially designed to target mitochondria by conjugating or surface modified with mitochondria targeting moiety.</p><p>Most human tumors are MHC class II negative, which CD4<sup>+</sup> T cells cannot recognize. NPs have potential to elicit the immunomodulatory cytokines which favor the proliferation and differentiation of cell-mediated immunity. Sena <italic toggle="yes">et al.</italic> [<xref rid="B13-vaccines-04-00018" ref-type="bibr">13</xref>] reported that increased mitochondrial ROS was able to produce nuclear factor of activated T cells and subsequent IL-2 cytokine expression. Specifically, the study demonstrated that mitochondrial complex III ROS is required for CD4<sup>+</sup> T cell activation in mice model. The Uqcrfs1<sup>&#8722;/&#8722;</sup> T cells, lacking mitochondrial complex III ROS and mitochondrial production of ATP, and controls WT CD4<sup>+</sup> T cells were isolated from Cd4-cre mice, which had the same cell viability after 24 h of cell culture. The Uqcrfs1<sup>&#8722;/&#8722;</sup> CD4<sup>+</sup> T cells failed to induce IL-2 and were less activated (reduced CD69 and CD25 markers) in response to anti-CD3 and anti-CD28 stimulation. Hence, mitochondria targeting to immune cells (e.g., T cell, natural killer cells) by NP-systems can be a promising method to enhance cytokine generation efficiency <italic toggle="yes">via</italic> mitochondria pathways.</p><p>Some efforts were made towards using NPs to potentiate cytokine generation for immune response. For example, Hanley <italic toggle="yes">et al.</italic> [<xref rid="B185-vaccines-04-00018" ref-type="bibr">185</xref>] reported ZnO NPs as modulators of pro-inflammatory cytokines, IFN-<italic toggle="yes">&#947;</italic>, TNF-&#945;, and IL-12 in primary human immune cells. ZnO NPs with size range of 4&#8211;20 nm were prepared by forced hydrolysis of zinc acetate. The 8-nm ZnO NPs were used to evaluate the generation of cytokines of immune cells in isolated peripheral blood mononuclear cells (PBMC). A pretreatment with low level of IFN-<italic toggle="yes">&#947;</italic> before treatment by ZnO NPs resulted in a significant amount of IL-12 expression, indicative of a synergistic relationship between ZnO NPs and IFN-<italic toggle="yes">&#947;</italic>. The ZnO NP treated PBMC showed significant enhancement of IL-12, IFN-<italic toggle="yes">&#947;</italic>, and TNF-&#945; cytokine levels, which were dose dependent for ZnO NP. The cytokines (IFN-<italic toggle="yes">&#947;</italic>, TNF-&#945;, and IL-12) produced by ZnO NPs aided in antigen processing and immune cell differentiation for enhanced destruction of cancerous cells, virally infected cells, and/or intracellular pathogens. ZnO NPs are also reported to enhance inflammatory cytokines levels in murine macrophages [<xref rid="B186-vaccines-04-00018" ref-type="bibr">186</xref>]. Liu <italic toggle="yes">et al.</italic> [<xref rid="B187-vaccines-04-00018" ref-type="bibr">187</xref>] reported that poly-hydroxylated metallofullerenol [Gd@C<sub>82</sub>(OH)<sub>22</sub>]<sub>n</sub> modulates levels of Th1 (IL-2, IFN-<italic toggle="yes">&#947;</italic>, and TNF-<italic toggle="yes">&#945;</italic>) and Th2 (IL-4, IL-5, and IL-6) cytokines in T cells and macrophages. The ratio of CD4<sup>+</sup> to CD8<sup>+</sup> T cells was significantly increased by [Gd@C<sub>82</sub>(OH)<sub>22</sub>]<sub>n</sub> treatment. Polyvinylpyrrolidone (PVP)-PEG-Ag nanorods were reported for HIV vaccine [<xref rid="B188-vaccines-04-00018" ref-type="bibr">188</xref>]. Au NPs were modified with glycopolymer to be used as synthetic cancer vaccines [<xref rid="B189-vaccines-04-00018" ref-type="bibr">189</xref>] and showed strong antibody production. Further modification of these sets of NPs by mitochondria targeting moiety can potentially modulate immune response.</p></sec><sec id="sec5-vaccines-04-00018"><title>5. Conclusions and Future Outlook</title><p>Mitochondria play critical roles in cell life and death, and their dysfunction is indicative of mitochondria-associated diseases. An ever-increasing number of investigations are focused on mitochondria targeting for efficient disease therapeutics, indicating the potential for such strategy in preventive/therapeutic vaccine. Possible roles for targeting mitochondria in vaccine development can be: (1) as targets of APCs (e.g., DCs) for external antigen delivery systems; (2) as targeting sites of immune cells activation (e.g., T and B cell); (3) as targets in dysfunctional cells (e.g., tumor cells) for apoptosis and production of TAAs available for APC uptake and subsequent activation of immune cells. NP-based vaccine systems are promising for: (1) carriers for delivery of external antigens; (2) inducers of apoptosis for release of internal antigens; and/or (3) inducers of cytokine production <italic toggle="yes">via</italic> due to their intrinsic properties. There are relatively fewer studies concerning mitochondria-targeted NP vaccine delivery systems. Mitochondrial targeting NP systems can provide for both cell-mediated (Th1; CD8<sup>+</sup> T cell) and humoral (Th2; B cell) immune response <italic toggle="yes">via</italic> activation of various pathways, such as complex III, ROS, and are promising tools for vaccines with effective immune responses. To achieve the mitochondria targeting purpose, the well-developed antigen nanocarriers, consisting of polymer-based and liposome-based antigen delivery systems, should be modified with a mitochondria targeting moiety, such as TPP or MTS, in order to direct antigen systems to the mitochondria. NP based vaccine delivery system has been shown to be a promising method for enhancing vaccine efficacies and can potentially be translated in to a worldwide immunization scope in the near future.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank the Department of Defense Prostate Cancer Idea award (W81XWH-12-1-0406); American Heart Association National Scientist Award (14SDG18690009); National Heart, Lung, and Blood Institute of National Institutes of Health (NIH) under award number R56HL121392; National Institute of Neurological Disorders and Stroke of NIH under award number R01NS093314 and Georgia Research Alliance for supporting various projects related to nanoparticle-based technologies in our lab.</p></ack><notes><title>Author Contributions</title><p>R.W., A.C.U., L.F., S.T. and S.D. wrote the paper. N.S. participated in the construction of <xref ref-type="table" rid="vaccines-04-00018-t002">Table 2</xref>.</p></notes><notes><title>Conflicts of Interest</title><p>S.D. discloses financial interest in Partikula LLC. All other authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-04-00018"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M.A.</given-names></name></person-group><article-title>Immunologic basis of vaccine vectors</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>504</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.004</pub-id><pub-id pub-id-type="pmid">21029961</pub-id></element-citation></ref><ref id="B2-vaccines-04-00018"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geels</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>K.</given-names></name></person-group><article-title>Developments in high-yield system expressed vaccines and immunotherapy</article-title><source>Recent Pat. Biotechnol.</source><year>2010</year><volume>4</volume><fpage>189</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.2174/187220810793611518</pub-id><pub-id pub-id-type="pmid">21171956</pub-id><pub-id pub-id-type="pmcid">PMC3020102</pub-id></element-citation></ref><ref id="B3-vaccines-04-00018"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irvine</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Rakhra</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tokatlian</surname><given-names>T.</given-names></name></person-group><article-title>Synthetic nanoparticles for vaccines and immunotherapy</article-title><source>Chem. Rev.</source><year>2015</year><volume>115</volume><fpage>11109</fpage><lpage>11146</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.5b00109</pub-id><pub-id pub-id-type="pmid">26154342</pub-id><pub-id pub-id-type="pmcid">PMC4688911</pub-id></element-citation></ref><ref id="B4-vaccines-04-00018"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rice-Ficht</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Arenas-Gamboa</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kahl-McDonagh</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Ficht</surname><given-names>T.A.</given-names></name></person-group><article-title>Polymeric particles in vaccine delivery</article-title><source>Curr. Opin. Microbiol.</source><year>2010</year><volume>13</volume><fpage>106</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2009.12.001</pub-id><pub-id pub-id-type="pmid">20079678</pub-id></element-citation></ref><ref id="B5-vaccines-04-00018"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachmann</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>G.T.</given-names></name></person-group><article-title>Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns</article-title><source>Nat. Rev. Immunol.</source><year>2010</year><volume>10</volume><fpage>787</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1038/nri2868</pub-id><pub-id pub-id-type="pmid">20948547</pub-id></element-citation></ref><ref id="B6-vaccines-04-00018"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Seth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wibowo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Mitter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Middelberg</surname><given-names>A.P.</given-names></name></person-group><article-title>Nanoparticle vaccines</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.11.069</pub-id><pub-id pub-id-type="pmid">24295808</pub-id></element-citation></ref><ref id="B7-vaccines-04-00018"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Banik</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kolishetti</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title>Nanotechnology inspired tools for mitochondrial dysfunction related diseases</article-title><source>Adv. Drug Deliv. Rev.</source><year>2016</year><volume>99</volume><fpage>52</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2015.12.024</pub-id><pub-id pub-id-type="pmid">26776231</pub-id><pub-id pub-id-type="pmcid">PMC4798867</pub-id></element-citation></ref><ref id="B8-vaccines-04-00018"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>D.C.</given-names></name></person-group><article-title>Mitochondria: Dynamic organelles in disease, aging, and development</article-title><source>Cell</source><year>2006</year><volume>125</volume><fpage>1241</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.06.010</pub-id><pub-id pub-id-type="pmid">16814712</pub-id></element-citation></ref><ref id="B9-vaccines-04-00018"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pathak</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Kolishetti</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title>Targeted nanoparticles in mitochondrial medicine</article-title><source>Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.</source><year>2015</year><volume>7</volume><fpage>315</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1002/wnan.1305</pub-id><pub-id pub-id-type="pmid">25348382</pub-id><pub-id pub-id-type="pmcid">PMC4397104</pub-id></element-citation></ref><ref id="B10-vaccines-04-00018"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duchen</surname><given-names>M.R.</given-names></name></person-group><article-title>Mitochondria in health and disease: Perspectives on a new mitochondrial biology</article-title><source>Mol. Aspects Med.</source><year>2004</year><volume>25</volume><fpage>365</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2004.03.001</pub-id><pub-id pub-id-type="pmid">15302203</pub-id></element-citation></ref><ref id="B11-vaccines-04-00018"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrache</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar Pathak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Darley</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Zaver</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kolishetti</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title>Nanocarriers for tracking and treating diseases</article-title><source>Curr. Med. Chem.</source><year>2013</year><volume>20</volume><fpage>3500</fpage><lpage>3514</lpage><pub-id pub-id-type="doi">10.2174/0929867311320280007</pub-id><pub-id pub-id-type="pmid">23834187</pub-id><pub-id pub-id-type="pmcid">PMC8085808</pub-id></element-citation></ref><ref id="B12-vaccines-04-00018"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Shadel</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>S.</given-names></name></person-group><article-title>Mitochondria in innate immune responses</article-title><source>Nat. Rev. Immunol.</source><year>2011</year><volume>11</volume><fpage>389</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1038/nri2975</pub-id><pub-id pub-id-type="pmid">21597473</pub-id><pub-id pub-id-type="pmcid">PMC4281487</pub-id></element-citation></ref><ref id="B13-vaccines-04-00018"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sena</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jairaman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Prakriya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ezponda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hildeman</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Schumacker</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Licht</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling</article-title><source>Immunity</source><year>2013</year><volume>38</volume><fpage>225</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.10.020</pub-id><pub-id pub-id-type="pmid">23415911</pub-id><pub-id pub-id-type="pmcid">PMC3582741</pub-id></element-citation></ref><ref id="B14-vaccines-04-00018"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine</article-title><source>J. Control. Release</source><year>2008</year><volume>130</volume><fpage>22</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2008.05.005</pub-id><pub-id pub-id-type="pmid">18554742</pub-id></element-citation></ref><ref id="B15-vaccines-04-00018"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeaman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Danner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mutimer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fussey</surname><given-names>S.</given-names></name><name name-style="western"><surname>James</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bassendine</surname><given-names>M.</given-names></name></person-group><article-title>Primary biliary cirrhosis: Identification of two major M2 mitochondrial autoantigens</article-title><source>Lancet</source><year>1988</year><volume>331</volume><fpage>1067</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(88)91894-6</pub-id><pub-id pub-id-type="pmid">2896910</pub-id></element-citation></ref><ref id="B16-vaccines-04-00018"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fussey</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Lindsay</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perham</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Dale</surname><given-names>S.</given-names></name><name name-style="western"><surname>James</surname><given-names>O.F.</given-names></name><name name-style="western"><surname>Bassendine</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Yeaman</surname><given-names>S.J.</given-names></name></person-group><article-title>Autoantibodies in primary biliary cirrhosis: Analysis of reactivity against eukaryotic and prokaryotic 2-oxo acid dehydrogenase complexes</article-title><source>Hepatology</source><year>1991</year><volume>13</volume><fpage>467</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1002/hep.1840130314</pub-id><pub-id pub-id-type="pmid">1999318</pub-id></element-citation></ref><ref id="B17-vaccines-04-00018"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moteki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Van Thiel</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Galperin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Buch</surname><given-names>T.</given-names></name><name name-style="western"><surname>Alarcon-Segovia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kershenobich</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kawano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Coppel</surname><given-names>R.L.</given-names></name></person-group><article-title>Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2*oxoglutarate dehydrogenase complex</article-title><source>Hepatology</source><year>1996</year><volume>23</volume><fpage>436</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1002/hep.510230307</pub-id><pub-id pub-id-type="pmid">8617422</pub-id></element-citation></ref><ref id="B18-vaccines-04-00018"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Duvvuri</surname><given-names>B.</given-names></name><name name-style="western"><surname>Grigull</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jamnik</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wither</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.E.</given-names></name></person-group><article-title>Experimental evidence that mutated-self peptides derived from mitochondrial DNA somatic mutations have the potential to trigger autoimmunity</article-title><source>Hum. Immunol.</source><year>2014</year><volume>75</volume><fpage>873</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2014.06.012</pub-id><pub-id pub-id-type="pmid">24979674</pub-id></element-citation></ref><ref id="B19-vaccines-04-00018"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gershwin</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sturgess</surname><given-names>A.</given-names></name><name name-style="western"><surname>Coppel</surname><given-names>R.</given-names></name></person-group><article-title>Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis</article-title><source>J. Immunol.</source><year>1987</year><volume>138</volume><fpage>3525</fpage><lpage>3531</lpage><pub-id pub-id-type="pmid">3571977</pub-id></element-citation></ref><ref id="B20-vaccines-04-00018"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrache</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tundup</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harn</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title><italic toggle="yes">Ex vivo</italic> programming of dendritic cells by mitochondria-targeted nanoparticles to produce interferon-gamma for cancer immunotherapy</article-title><source>ACS Nano</source><year>2013</year><volume>7</volume><fpage>7392</fpage><lpage>7402</lpage><pub-id pub-id-type="doi">10.1021/nn403158n</pub-id><pub-id pub-id-type="pmid">23899410</pub-id></element-citation></ref><ref id="B21-vaccines-04-00018"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pierini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rafail</surname><given-names>S.</given-names></name><name name-style="western"><surname>Facciponte</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Sanctis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Uribe-Herranz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tanyi</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Facciabene</surname><given-names>A.</given-names></name></person-group><article-title>A tumor mitochondria vaccine protects against experimental renal cell carcinoma</article-title><source>J. Immunol.</source><year>2015</year><volume>195</volume><fpage>4020</fpage><lpage>4027</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1500281</pub-id><pub-id pub-id-type="pmid">26378078</pub-id></element-citation></ref><ref id="B22-vaccines-04-00018"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Khoury-Hanold</surname><given-names>W.</given-names></name><name name-style="western"><surname>Staron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tal</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Pineda</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Bestwick</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duguay</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Raimundo</surname><given-names>N.</given-names></name><name name-style="western"><surname>MacDuff</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>Mitochondrial DNA stress primes the antiviral innate immune response</article-title><source>Nature</source><year>2015</year><volume>520</volume><fpage>553</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1038/nature14156</pub-id><pub-id pub-id-type="pmid">25642965</pub-id><pub-id pub-id-type="pmcid">PMC4409480</pub-id></element-citation></ref><ref id="B23-vaccines-04-00018"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>R.</given-names></name><name name-style="western"><surname>Huston</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Huston</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Rich</surname><given-names>R.R.</given-names></name></person-group><article-title>Mitochondria control expression of a murine cell surface antigen</article-title><source>Nature</source><year>1983</year><volume>306</volume><fpage>599</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1038/306599a0</pub-id><pub-id pub-id-type="pmid">6606133</pub-id></element-citation></ref><ref id="B24-vaccines-04-00018"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loveland</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Yonekawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hermel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lindahl</surname><given-names>K.F.</given-names></name></person-group><article-title>Maternally transmitted histocompatibility antigen of mice: A hydrophobic peptide of a mitochondrially encoded protein</article-title><source>Cell</source><year>1990</year><volume>60</volume><fpage>971</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(90)90345-F</pub-id><pub-id pub-id-type="pmid">2317868</pub-id></element-citation></ref><ref id="B25-vaccines-04-00018"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matsumura</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.S.</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>Z.X.</given-names></name><name name-style="western"><surname>Van de Water</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coppel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Gershwin</surname><given-names>M.E.</given-names></name></person-group><article-title>Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis</article-title><source>J. Clin. Invest.</source><year>2002</year><volume>109</volume><fpage>1231</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1172/JCI0214698</pub-id><pub-id pub-id-type="pmid">11994412</pub-id><pub-id pub-id-type="pmcid">PMC150963</pub-id></element-citation></ref><ref id="B26-vaccines-04-00018"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mondi&#232;re</surname><given-names>P.</given-names></name><name name-style="western"><surname>Casamayor-Pallej&#224;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hennino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bella</surname><given-names>C.</given-names></name><name name-style="western"><surname>Defrance</surname><given-names>T.</given-names></name></person-group><article-title>Mitochondria connects the antigen receptor to effector caspases during B cell receptor-induced apoptosis in normal human B cells</article-title><source>J. Immunol.</source><year>1999</year><volume>163</volume><fpage>4655</fpage><lpage>4662</lpage><pub-id pub-id-type="pmid">10528162</pub-id></element-citation></ref><ref id="B27-vaccines-04-00018"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrache</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tundup</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harn</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title><italic toggle="yes">Ex Vivo</italic> Generation of functional immune cells by mitochondria-targeted photosensitization of cancer cells</article-title><source>Methods Mol. Biol.</source><year>2015</year><volume>2</volume><fpage>113</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">25634271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-2288-8_9</pub-id></element-citation></ref><ref id="B28-vaccines-04-00018"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrache</surname><given-names>S.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Tundup</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zaver</surname><given-names>D.</given-names></name><name name-style="western"><surname>Harn</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title>Immune stimulating photoactive hybrid nanoparticles for metastatic breast cancer</article-title><source>Integr. Biol.</source><year>2013</year><volume>5</volume><fpage>215</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1039/C2IB20125A</pub-id><pub-id pub-id-type="pmid">22832596</pub-id><pub-id pub-id-type="pmcid">PMC3524336</pub-id></element-citation></ref><ref id="B29-vaccines-04-00018"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panneerselvam</surname><given-names>P.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Selvarajan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chng</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.L.</given-names></name></person-group><article-title>T-cell death following immune activation is mediated by mitochondria-localized SARM</article-title><source>Cell Death Differ.</source><year>2013</year><volume>20</volume><fpage>478</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1038/cdd.2012.144</pub-id><pub-id pub-id-type="pmid">23175186</pub-id><pub-id pub-id-type="pmcid">PMC3569988</pub-id></element-citation></ref><ref id="B30-vaccines-04-00018"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van de Water</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Surh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coppel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roche</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bonkovsky</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gershwin</surname><given-names>M.</given-names></name></person-group><article-title>Evidence for the targeting by 2-oxo-dehydrogenase enzymes in the T cell response of primary biliary cirrhosis</article-title><source>J. Immunol.</source><year>1991</year><volume>146</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">1984455</pub-id></element-citation></ref><ref id="B31-vaccines-04-00018"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.M.</given-names></name></person-group><article-title>Mitochondrial ROS fire up T cell activation</article-title><source>Immunity</source><year>2013</year><volume>38</volume><fpage>201</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.02.005</pub-id><pub-id pub-id-type="pmid">23438817</pub-id></element-citation></ref><ref id="B32-vaccines-04-00018"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Storni</surname><given-names>T.</given-names></name><name name-style="western"><surname>K&#252;ndig</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Senti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Johansen</surname><given-names>P.</given-names></name></person-group><article-title>Immunity in response to particulate antigen-delivery systems</article-title><source>Adv. Drug Deliv. Rev.</source><year>2005</year><volume>57</volume><fpage>333</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2004.09.008</pub-id><pub-id pub-id-type="pmid">15560945</pub-id></element-citation></ref><ref id="B33-vaccines-04-00018"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jewell</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>D.J.</given-names></name></person-group><article-title><italic toggle="yes">In situ</italic> engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>15745</fpage><lpage>15750</lpage><pub-id pub-id-type="doi">10.1073/pnas.1105200108</pub-id><pub-id pub-id-type="pmid">21896725</pub-id><pub-id pub-id-type="pmcid">PMC3179077</pub-id></element-citation></ref><ref id="B34-vaccines-04-00018"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demento</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>W.</given-names></name><name name-style="western"><surname>Criscione</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tulipan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaech</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Fahmy</surname><given-names>T.M.</given-names></name></person-group><article-title>Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype</article-title><source>Biomaterials</source><year>2012</year><volume>33</volume><fpage>4957</fpage><lpage>4964</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.03.041</pub-id><pub-id pub-id-type="pmid">22484047</pub-id><pub-id pub-id-type="pmcid">PMC5724530</pub-id></element-citation></ref><ref id="B35-vaccines-04-00018"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahimian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kleinovink</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Fransen</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Mezzanotte</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gold</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wisse</surname><given-names>P.</given-names></name><name name-style="western"><surname>Overkleeft</surname><given-names>H.</given-names></name><name name-style="western"><surname>Amidi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W.</given-names></name><name name-style="western"><surname>L&#246;wik</surname><given-names>C.W.</given-names></name></person-group><article-title>Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: <italic toggle="yes">In vivo</italic> tracking and evaluation of antigen-specific CD8<sup>+</sup> T cell immune response</article-title><source>Biomaterials</source><year>2015</year><volume>37</volume><fpage>469</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.10.043</pub-id><pub-id pub-id-type="pmid">25453974</pub-id></element-citation></ref><ref id="B36-vaccines-04-00018"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahimian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fransen</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Kleinovink</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Amidi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hennink</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Ossendorp</surname><given-names>F.</given-names></name></person-group><article-title>Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation</article-title><source>J. Control. Release</source><year>2015</year><volume>203</volume><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.02.006</pub-id><pub-id pub-id-type="pmid">25660830</pub-id></element-citation></ref><ref id="B37-vaccines-04-00018"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruz</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Tacken</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Fokkink</surname><given-names>R.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Albericio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Torensma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Figdor</surname><given-names>C.G.</given-names></name></person-group><article-title>Targeted PLGA nano-but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN <italic toggle="yes">in vitro</italic></article-title><source>J. Control. Release</source><year>2010</year><volume>144</volume><fpage>118</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2010.02.013</pub-id><pub-id pub-id-type="pmid">20156497</pub-id></element-citation></ref><ref id="B38-vaccines-04-00018"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chong</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Addison</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Tyrrell</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>J.</given-names></name></person-group><article-title>Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery</article-title><source>J. Control. Release</source><year>2005</year><volume>102</volume><fpage>85</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2004.09.014</pub-id><pub-id pub-id-type="pmid">15653136</pub-id></element-citation></ref><ref id="B39-vaccines-04-00018"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wendorf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chesko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kazzaz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ugozzoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vajdy</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name></person-group><article-title>A comparison of anionic nanoparticles and microparticles as vaccine delivery systems</article-title><source>Hum. Vaccin.</source><year>2008</year><volume>4</volume><fpage>44</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.4161/hv.4.1.4886</pub-id><pub-id pub-id-type="pmid">18438105</pub-id></element-citation></ref><ref id="B40-vaccines-04-00018"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solbrig</surname><given-names>C.</given-names></name><name name-style="western"><surname>Saucier-Sawyer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cody</surname><given-names>V.</given-names></name><name name-style="western"><surname>Saltzman</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hanlon</surname><given-names>D.</given-names></name></person-group><article-title>Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells</article-title><source>Mol. Pharm.</source><year>2007</year><volume>4</volume><fpage>47</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1021/mp060107e</pub-id><pub-id pub-id-type="pmid">17217312</pub-id></element-citation></ref><ref id="B41-vaccines-04-00018"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diwan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elamanchili</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>J.</given-names></name></person-group><article-title>Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery</article-title><source>Curr. Drug Deliv.</source><year>2004</year><volume>1</volume><fpage>405</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.2174/1567201043334597</pub-id><pub-id pub-id-type="pmid">16305402</pub-id></element-citation></ref><ref id="B42-vaccines-04-00018"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danhier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ansorena</surname><given-names>E.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Coco</surname><given-names>R.</given-names></name><name name-style="western"><surname>Le Breton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pr&#233;at</surname><given-names>V.</given-names></name></person-group><article-title>PLGA-based nanoparticles: An overview of biomedical applications</article-title><source>J. Control. Release</source><year>2012</year><volume>161</volume><fpage>505</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2012.01.043</pub-id><pub-id pub-id-type="pmid">22353619</pub-id></element-citation></ref><ref id="B43-vaccines-04-00018"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamdy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Molavi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Haddadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alshamsan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gobti</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Elhasi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lavasanifar</surname><given-names>A.</given-names></name></person-group><article-title>Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8<sup>+</sup> T cell-mediated anti-tumor immunity</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>5046</fpage><lpage>5057</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.07.035</pub-id><pub-id pub-id-type="pmid">18680779</pub-id></element-citation></ref><ref id="B44-vaccines-04-00018"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruz</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Tacken</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Fokkink</surname><given-names>R.</given-names></name><name name-style="western"><surname>Figdor</surname><given-names>C.G.</given-names></name></person-group><article-title>The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><fpage>6791</fpage><lpage>6803</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.04.082</pub-id><pub-id pub-id-type="pmid">21724247</pub-id></element-citation></ref><ref id="B45-vaccines-04-00018"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bivas-Benita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Bal</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>van Meijgaarden</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Franken</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Friggen</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Junginger</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Borchard</surname><given-names>G.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Ottenhoff</surname><given-names>T.H.</given-names></name></person-group><article-title>Pulmonary delivery of DNA encoding <italic toggle="yes">Mycobacterium tuberculosis</italic> latency antigen Rv1733c associated to PLGA&#8211;PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>4010</fpage><lpage>4017</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.04.033</pub-id><pub-id pub-id-type="pmid">19389445</pub-id></element-citation></ref><ref id="B46-vaccines-04-00018"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prego</surname><given-names>C.</given-names></name><name name-style="western"><surname>Paolicelli</surname><given-names>P.</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vicente</surname><given-names>S.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Fern&#225;ndez</surname><given-names>&#193;.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>M.J.</given-names></name></person-group><article-title>Chitosan-based nanoparticles for improving immunization against hepatitis B infection</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>2607</fpage><lpage>2614</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.01.011</pub-id><pub-id pub-id-type="pmid">20096389</pub-id></element-citation></ref><ref id="B47-vaccines-04-00018"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barzegar-Jalali</surname><given-names>M.</given-names></name></person-group><article-title>Nanovaccine for leishmaniasis: Preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice</article-title><source>Int. J. Nanomedicine</source><year>2011</year><volume>6</volume><fpage>835</fpage><lpage>842</lpage><pub-id pub-id-type="pmid">21589651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S16805</pub-id><pub-id pub-id-type="pmcid">PMC3090280</pub-id></element-citation></ref><ref id="B48-vaccines-04-00018"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vila</surname><given-names>A.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Janes</surname><given-names>K.</given-names></name><name name-style="western"><surname>Behrens</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kissel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jato</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>M.J.</given-names></name></person-group><article-title>Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2004</year><volume>57</volume><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2003.09.006</pub-id><pub-id pub-id-type="pmid">14729088</pub-id></element-citation></ref><ref id="B49-vaccines-04-00018"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Correia-Pinto</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Csaba</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schiller</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>M.J.</given-names></name></person-group><article-title>Chitosan-poly (I: C)-PADRE based nanoparticles as delivery vehicles for synthetic peptide vaccines</article-title><source>Vaccines</source><year>2015</year><volume>3</volume><fpage>730</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.3390/vaccines3030730</pub-id><pub-id pub-id-type="pmid">26378586</pub-id><pub-id pub-id-type="pmcid">PMC4586475</pub-id></element-citation></ref><ref id="B50-vaccines-04-00018"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Perera</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hintzen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kotti</surname><given-names>K.</given-names></name><name name-style="western"><surname>Karageorgiou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kammona</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kiparissides</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bernkop-Schn&#252;rch</surname><given-names>A.</given-names></name></person-group><article-title><italic toggle="yes">In vivo</italic> evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><fpage>4052</fpage><lpage>4057</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.02.011</pub-id><pub-id pub-id-type="pmid">21377204</pub-id></element-citation></ref><ref id="B51-vaccines-04-00018"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ataman-&#214;nal</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Munier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gan&#233;e</surname><given-names>A.</given-names></name><name name-style="western"><surname>Terrat</surname><given-names>C.</given-names></name><name name-style="western"><surname>Durand</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Battail</surname><given-names>N.</given-names></name><name name-style="western"><surname>Martinon</surname><given-names>F.</given-names></name><name name-style="western"><surname>Le Grand</surname><given-names>R.</given-names></name><name name-style="western"><surname>Charles</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Delair</surname><given-names>T.</given-names></name></person-group><article-title>Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models</article-title><source>J. Control. Release</source><year>2006</year><volume>112</volume><fpage>175</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2006.02.006</pub-id><pub-id pub-id-type="pmid">16563545</pub-id></element-citation></ref><ref id="B52-vaccines-04-00018"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yoshii</surname><given-names>H.</given-names></name><name name-style="western"><surname>Akagi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okuno</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamanishi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>Y.</given-names></name></person-group><article-title>Influenza hemagglutinin vaccine with poly (&#947;-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>8270</fpage><lpage>8278</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.09.051</pub-id><pub-id pub-id-type="pmid">17977633</pub-id></element-citation></ref><ref id="B53-vaccines-04-00018"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pandit</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bramwell</surname><given-names>V.W.</given-names></name><name name-style="western"><surname>Alpar</surname><given-names>H.O.</given-names></name></person-group><article-title>Diphtheria toxoid loaded poly-(&#949;-caprolactone) nanoparticles as mucosal vaccine delivery systems</article-title><source>Methods</source><year>2006</year><volume>38</volume><fpage>96</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2005.11.003</pub-id><pub-id pub-id-type="pmid">16442811</pub-id></element-citation></ref><ref id="B54-vaccines-04-00018"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirosue</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kourtis</surname><given-names>I.C.</given-names></name><name name-style="western"><surname>van der Vlies</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>M.A.</given-names></name></person-group><article-title>Antigen delivery to dendritic cells by poly (propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>7897</fpage><lpage>7906</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.09.077</pub-id><pub-id pub-id-type="pmid">20934457</pub-id></element-citation></ref><ref id="B55-vaccines-04-00018"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rawat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hope-Weeks</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ahsan</surname><given-names>F.</given-names></name></person-group><article-title>Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine</article-title><source>Mol. Pharm.</source><year>2011</year><volume>8</volume><fpage>405</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1021/mp100255c</pub-id><pub-id pub-id-type="pmid">21189035</pub-id></element-citation></ref><ref id="B56-vaccines-04-00018"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrache</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title>Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>16288</fpage><lpage>16293</lpage><pub-id pub-id-type="doi">10.1073/pnas.1210096109</pub-id><pub-id pub-id-type="pmid">22991470</pub-id><pub-id pub-id-type="pmcid">PMC3479596</pub-id></element-citation></ref><ref id="B57-vaccines-04-00018"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vaidya</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mangal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vyas</surname><given-names>S.P.</given-names></name></person-group><article-title>PEG-PLA-PEG block copolymeric nanoparticles for oral immunization against hepatitis B</article-title><source>Int. J. Pharm.</source><year>2010</year><volume>387</volume><fpage>253</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2009.12.013</pub-id><pub-id pub-id-type="pmid">20005936</pub-id></element-citation></ref><ref id="B58-vaccines-04-00018"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z.</given-names></name></person-group><article-title>Preparation of mannan modified anionic PCL&#8211;PEG&#8211;PCL nanoparticles at one-step for bFGF antigen delivery to improve humoral immunity</article-title><source>Colloids Surf. B: Biointerfaces</source><year>2008</year><volume>64</volume><fpage>135</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2007.12.014</pub-id><pub-id pub-id-type="pmid">18249528</pub-id></element-citation></ref><ref id="B59-vaccines-04-00018"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sl&#252;tter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Keijzer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mallants</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hagenaars</surname><given-names>N.</given-names></name><name name-style="western"><surname>Que</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kaijzel</surname><given-names>E.</given-names></name><name name-style="western"><surname>van Eden</surname><given-names>W.</given-names></name><name name-style="western"><surname>Augustijns</surname><given-names>P.</given-names></name><name name-style="western"><surname>L&#246;wik</surname><given-names>C.</given-names></name></person-group><article-title>Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: Nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>6282</fpage><lpage>6291</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.06.121</pub-id><pub-id pub-id-type="pmid">20638455</pub-id></element-citation></ref><ref id="B60-vaccines-04-00018"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ito</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shinkai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Honda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name></person-group><article-title>Medical application of functionalized magnetic nanoparticles</article-title><source>J. Biosci. Bioeng.</source><year>2005</year><volume>100</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1263/jbb.100.1</pub-id><pub-id pub-id-type="pmid">16233845</pub-id></element-citation></ref><ref id="B61-vaccines-04-00018"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellens</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bentz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Szoka</surname><given-names>F.C.</given-names></name></person-group><article-title>Fusion of phosphatidylethanolamine-containing liposomes and mechanism of L. alpha.-HII phase transition</article-title><source>Biochemistry</source><year>1986</year><volume>25</volume><fpage>4141</fpage><lpage>4147</lpage><pub-id pub-id-type="doi">10.1021/bi00362a023</pub-id><pub-id pub-id-type="pmid">3741846</pub-id></element-citation></ref><ref id="B62-vaccines-04-00018"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Mumper</surname><given-names>R.J.</given-names></name></person-group><article-title>The effect of co-administration of adjuvants with a nanoparticle-based genetic vaccine delivery system on the resulting immune responses</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2003</year><volume>55</volume><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/S0939-6411(02)00129-7</pub-id><pub-id pub-id-type="pmid">12551699</pub-id></element-citation></ref><ref id="B63-vaccines-04-00018"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnamachari</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Geary</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lemke</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>A.K.</given-names></name></person-group><article-title>Nanoparticle delivery systems in cancer vaccines</article-title><source>Pharm. Res.</source><year>2011</year><volume>28</volume><fpage>215</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1007/s11095-010-0241-4</pub-id><pub-id pub-id-type="pmid">20721603</pub-id><pub-id pub-id-type="pmcid">PMC3559243</pub-id></element-citation></ref><ref id="B64-vaccines-04-00018"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diebold</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jarr&#237;n</surname><given-names>M.</given-names></name><name name-style="western"><surname>S&#225;ez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Orea</surname><given-names>M.</given-names></name><name name-style="western"><surname>Calonge</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seijo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>M.J.</given-names></name></person-group><article-title>Ocular drug delivery by liposome&#8211;chitosan nanoparticle complexes (LCS-NP)</article-title><source>Biomaterials</source><year>2007</year><volume>28</volume><fpage>1553</fpage><lpage>1564</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2006.11.028</pub-id><pub-id pub-id-type="pmid">17169422</pub-id></element-citation></ref><ref id="B65-vaccines-04-00018"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>J.H.</given-names></name></person-group><article-title>Enhanced adjuvantic property of polymerized liposome as compared to a phospholipid liposome</article-title><source>J. Biotechnol.</source><year>2002</year><volume>94</volume><fpage>255</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/S0168-1656(01)00430-8</pub-id><pub-id pub-id-type="pmid">11861084</pub-id></element-citation></ref><ref id="B66-vaccines-04-00018"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Torchilin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name></person-group><article-title>Polymerized liposomes as potential oral vaccine carriers: Stability and bioavailability</article-title><source>J. Control. Release</source><year>1996</year><volume>42</volume><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/0168-3659(96)01459-9</pub-id><pub-id pub-id-type="pmid">8893278</pub-id></element-citation></ref><ref id="B67-vaccines-04-00018"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malam</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Loizidou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seifalian</surname><given-names>A.M.</given-names></name></person-group><article-title>Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer</article-title><source>Trends Pharmacol. Sci.</source><year>2009</year><volume>30</volume><fpage>592</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2009.08.004</pub-id><pub-id pub-id-type="pmid">19837467</pub-id></element-citation></ref><ref id="B68-vaccines-04-00018"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhargava</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Varshney</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>P.K.</given-names></name></person-group><article-title>Assessment of tumor antigen-loaded solid lipid nanoparticles as an efficient delivery system for dendritic cell engineering</article-title><source>Nanomedicine</source><year>2013</year><volume>8</volume><fpage>1067</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.2217/nnm.12.164</pub-id><pub-id pub-id-type="pmid">23311961</pub-id></element-citation></ref><ref id="B69-vaccines-04-00018"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meidenbauer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>D.</given-names></name><name name-style="western"><surname>Spitler</surname><given-names>L.</given-names></name><name name-style="western"><surname>Whiteside</surname><given-names>T.</given-names></name></person-group><article-title>Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer</article-title><source>Prostate</source><year>2000</year><volume>43</volume><fpage>88</fpage><lpage>100</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1097-0045(20000501)43:2&amp;#x0003c;88::AID-PROS3&amp;#x0003e;3.0.CO;2-G</pub-id><pub-id pub-id-type="pmid">10754524</pub-id></element-citation></ref><ref id="B70-vaccines-04-00018"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>North</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bodnar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Venner</surname><given-names>P.</given-names></name></person-group><article-title>A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy</article-title><source>J. Urol.</source><year>2006</year><volume>176</volume><fpage>91</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(06)00494-0</pub-id><pub-id pub-id-type="pmid">16753376</pub-id></element-citation></ref><ref id="B71-vaccines-04-00018"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butts</surname><given-names>C.</given-names></name><name name-style="western"><surname>Socinski</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Thatcher</surname><given-names>N.</given-names></name><name name-style="western"><surname>Havel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Krzakowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nawrocki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ciuleanu</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Bosqu&#233;e</surname><given-names>L.</given-names></name><name name-style="western"><surname>Trigo</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Tecemotide (L-BLP25) <italic toggle="yes">versus</italic> placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial</article-title><source>Lancet Oncol.</source><year>2014</year><volume>15</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70510-2</pub-id><pub-id pub-id-type="pmid">24331154</pub-id></element-citation></ref><ref id="B72-vaccines-04-00018"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villa</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Dao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ahearn</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fehrenbacher</surname><given-names>N.</given-names></name><name name-style="western"><surname>Casey</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rey</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Korontsvit</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zakhaleva</surname><given-names>V.</given-names></name><name name-style="western"><surname>Batt</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Philips</surname><given-names>M.R.</given-names></name></person-group><article-title>Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens</article-title><source>ACS Nano</source><year>2011</year><volume>5</volume><fpage>5300</fpage><lpage>5311</lpage><pub-id pub-id-type="doi">10.1021/nn200182x</pub-id><pub-id pub-id-type="pmid">21682329</pub-id><pub-id pub-id-type="pmcid">PMC3143710</pub-id></element-citation></ref><ref id="B73-vaccines-04-00018"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name></person-group><article-title>Morphologies, preparations and applications of layered double hydroxide micro-/nanostructures</article-title><source>Materials</source><year>2010</year><volume>3</volume><fpage>5220</fpage><lpage>5235</lpage><pub-id pub-id-type="doi">10.3390/ma3125220</pub-id><pub-id pub-id-type="pmcid">PMC5445802</pub-id><pub-id pub-id-type="pmid">28883378</pub-id></element-citation></ref><ref id="B74-vaccines-04-00018"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z.P.</given-names></name><name name-style="western"><surname>Niebert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Porazik</surname><given-names>K.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Middelberg</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.Q.</given-names></name></person-group><article-title>Subcellular compartment targeting of layered double hydroxide nanoparticles</article-title><source>J. Control. Release</source><year>2008</year><volume>130</volume><fpage>86</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2008.05.021</pub-id><pub-id pub-id-type="pmid">18614254</pub-id></element-citation></ref><ref id="B75-vaccines-04-00018"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rolfe</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.P.</given-names></name></person-group><article-title>Polarized immune responses modulated by layered double hydroxides nanoparticle conjugated with CpG</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>9508</fpage><lpage>9516</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.07.055</pub-id><pub-id pub-id-type="pmid">25145853</pub-id></element-citation></ref><ref id="B76-vaccines-04-00018"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>The enhanced immune response of hepatitis B virus DNA vaccine using SiO<sub>2</sub>@LDH nanoparticles as an adjuvant</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>466</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2013.09.060</pub-id><pub-id pub-id-type="pmid">24099705</pub-id></element-citation></ref><ref id="B77-vaccines-04-00018"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Christopher</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Zabielski</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>J.</given-names></name></person-group><article-title>Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses</article-title><source>J. Clin. Virol.</source><year>2004</year><volume>31</volume><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2004.09.013</pub-id><pub-id pub-id-type="pmid">15567101</pub-id></element-citation></ref><ref id="B78-vaccines-04-00018"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ito</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>F.</given-names></name><name name-style="western"><surname>Honda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name></person-group><article-title>Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma</article-title><source>Cancer Immunol. Immunother.</source><year>2004</year><volume>53</volume><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/s00262-003-0416-5</pub-id><pub-id pub-id-type="pmid">14551746</pub-id><pub-id pub-id-type="pmcid">PMC11032910</pub-id></element-citation></ref><ref id="B79-vaccines-04-00018"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvarez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Echechipia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tabar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rico</surname><given-names>P.</given-names></name><name name-style="western"><surname>Olaguibel</surname><given-names>J.</given-names></name></person-group><article-title>Liposome-entrapped D. pteronyssinus vaccination in mild asthma patients: Effect of 1-year double-blind, placebo-controlled trial on inflammation, bronchial hyper-responsiveness and immediate and late bronchial responses to the allergen</article-title><source>Clin. Exp. Allergy</source><year>2002</year><volume>32</volume><fpage>1574</fpage><lpage>1582</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2222.2002.01514.x</pub-id><pub-id pub-id-type="pmid">12569977</pub-id></element-citation></ref><ref id="B80-vaccines-04-00018"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosada</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>de la Torre</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Frantz</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Trombone</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Z&#225;rate-Blad&#233;s</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Brand&#227;o</surname><given-names>I.T.</given-names></name><name name-style="western"><surname>Masson</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>&#201;.G.</given-names></name><etal/></person-group><article-title>Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes</article-title><source>BMC Immunol.</source><year>2008</year><volume>9</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1186/1471-2172-9-38</pub-id><pub-id pub-id-type="pmid">18647414</pub-id><pub-id pub-id-type="pmcid">PMC2500095</pub-id></element-citation></ref><ref id="B81-vaccines-04-00018"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Just</surname><given-names>M.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Drechsler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Brantschen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gl&#252;ck</surname><given-names>R.</given-names></name></person-group><article-title>A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks</article-title><source>Vaccine</source><year>1992</year><volume>10</volume><fpage>737</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(92)90506-F</pub-id><pub-id pub-id-type="pmid">1441728</pub-id></element-citation></ref><ref id="B82-vaccines-04-00018"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Borowski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Rinaldo</surname><given-names>C.R.</given-names></name></person-group><article-title>Delivery of liposome-encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1-specific memory cytotoxic T lymphocyte responses</article-title><source>AIDS Res. Hum. Retroviruses</source><year>1999</year><volume>15</volume><fpage>1011</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1089/088922299310520</pub-id><pub-id pub-id-type="pmid">10445813</pub-id></element-citation></ref><ref id="B83-vaccines-04-00018"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>Y.K.</given-names></name></person-group><article-title>Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy</article-title><source>Adv. Drug Deliv. Rev.</source><year>2009</year><volume>61</volume><fpage>233</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2008.12.014</pub-id><pub-id pub-id-type="pmid">19232375</pub-id></element-citation></ref><ref id="B84-vaccines-04-00018"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almeida</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Souto</surname><given-names>E.</given-names></name></person-group><article-title>Solid lipid nanoparticles as a drug delivery system for peptides and proteins</article-title><source>Adv. Drug Deliv. Rev.</source><year>2007</year><volume>59</volume><fpage>478</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2007.04.007</pub-id><pub-id pub-id-type="pmid">17543416</pub-id></element-citation></ref><ref id="B85-vaccines-04-00018"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: Therapeutic effect against cervical cancer</article-title><source>Cancer Immunol. Immunother.</source><year>2005</year><volume>54</volume><fpage>1180</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1007/s00262-005-0685-2</pub-id><pub-id pub-id-type="pmid">15846491</pub-id><pub-id pub-id-type="pmcid">PMC11032885</pub-id></element-citation></ref><ref id="B86-vaccines-04-00018"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kolar</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Zao</surname><given-names>M.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>C.</given-names></name></person-group><article-title>Localization of antimicrobial peptides on polymerized liposomes leading to their enhanced efficacy against Pseudomonas aeruginosa</article-title><source>Mol. BioSyst.</source><year>2011</year><volume>7</volume><fpage>711</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1039/c0mb00207k</pub-id><pub-id pub-id-type="pmid">21229178</pub-id><pub-id pub-id-type="pmcid">PMC3235330</pub-id></element-citation></ref><ref id="B87-vaccines-04-00018"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kossovsky</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gelman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hnatyszyn</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Rajguru</surname><given-names>S.</given-names></name><name name-style="western"><surname>Garrell</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Torbati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>G.M.</given-names></name></person-group><article-title>Surface-modified diamond nanoparticles as antigen delivery vehicles</article-title><source>Bioconjugate Chem.</source><year>1995</year><volume>6</volume><fpage>507</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1021/bc00035a001</pub-id><pub-id pub-id-type="pmid">8974446</pub-id></element-citation></ref><ref id="B88-vaccines-04-00018"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendon&#231;a</surname><given-names>E.</given-names></name><name name-style="western"><surname>Diniz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peres</surname><given-names>I.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>L.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Picado</surname><given-names>A.</given-names></name></person-group><article-title>Effects of diamond nanoparticle exposure on the internal structure and reproduction of Daphnia magna</article-title><source>J. Hazard Mater.</source><year>2011</year><volume>186</volume><fpage>265</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/j.jhazmat.2010.10.115</pub-id><pub-id pub-id-type="pmid">21111531</pub-id></element-citation></ref><ref id="B89-vaccines-04-00018"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Safari</surname><given-names>D.</given-names></name><name name-style="western"><surname>Marradi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chiodo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Th Dekker</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Oscarson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rijkers</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Lahmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kamerling</surname><given-names>J.P.</given-names></name></person-group><article-title>Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine</article-title><source>Nanomedicine</source><year>2012</year><volume>7</volume><fpage>651</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.2217/nnm.11.151</pub-id><pub-id pub-id-type="pmid">22630149</pub-id></element-citation></ref><ref id="B90-vaccines-04-00018"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>An</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Im</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Jon</surname><given-names>S.</given-names></name></person-group><article-title>Imageable Antigen-Presenting Gold Nanoparticle Vaccines for Effective Cancer Immunotherapy <italic toggle="yes">In Vivo</italic></article-title><source>Angew. Chem.</source><year>2012</year><volume>124</volume><fpage>8930</fpage><lpage>8935</lpage><pub-id pub-id-type="doi">10.1002/ange.201203193</pub-id><pub-id pub-id-type="pmid">22847719</pub-id></element-citation></ref><ref id="B91-vaccines-04-00018"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Parkinson</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Speshock</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>S.M.</given-names></name></person-group><article-title>A preliminary assessment of silver nanoparticle inhibition of monkeypox virus plaque formation</article-title><source>Nanoscale Res. Lett.</source><year>2008</year><volume>3</volume><fpage>129</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1007/s11671-008-9128-2</pub-id></element-citation></ref><ref id="B92-vaccines-04-00018"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lara</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Ayala-Nu&#241;ez</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Ixtepan-Turrent</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rodriguez-Padilla</surname><given-names>C.</given-names></name></person-group><article-title>Mode of antiviral action of silver nanoparticles against HIV-1</article-title><source>J. Nanobiotechnol.</source><year>2010</year><volume>8</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1186/1477-3155-8-1</pub-id><pub-id pub-id-type="pmid">20145735</pub-id><pub-id pub-id-type="pmcid">PMC2818642</pub-id></element-citation></ref><ref id="B93-vaccines-04-00018"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neutra</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Robey</surname><given-names>F.A.</given-names></name></person-group><article-title>Peptomer aluminum oxide nanoparticle conjugates as systemic and mucosal vaccine candidates: Synthesis and characterization of a conjugate derived from the C4 domain of HIV-1MN gp120</article-title><source>Bioconjugate Chem.</source><year>1997</year><volume>8</volume><fpage>424</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1021/bc970036p</pub-id><pub-id pub-id-type="pmid">9177850</pub-id></element-citation></ref><ref id="B94-vaccines-04-00018"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akagi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Toyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nishi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shima</surname><given-names>F.</given-names></name><name name-style="western"><surname>Akashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baba</surname><given-names>M.</given-names></name></person-group><article-title>Comparative activity of biodegradable nanoparticles with aluminum adjuvants: Antigen uptake by dendritic cells and induction of immune response in mice</article-title><source>Immunol. Lett.</source><year>2011</year><volume>140</volume><fpage>36</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2011.06.002</pub-id><pub-id pub-id-type="pmid">21693134</pub-id></element-citation></ref><ref id="B95-vaccines-04-00018"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Suh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bershteyn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stephan</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sohail</surname><given-names>M.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Um</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Khant</surname><given-names>H.</given-names></name></person-group><article-title>Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses</article-title><source>Nat. Mater.</source><year>2011</year><volume>10</volume><fpage>243</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/nmat2960</pub-id><pub-id pub-id-type="pmid">21336265</pub-id><pub-id pub-id-type="pmcid">PMC3077947</pub-id></element-citation></ref><ref id="B96-vaccines-04-00018"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plummer</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Manchester</surname><given-names>M.</given-names></name></person-group><article-title>Viral nanoparticles and virus-like particles: Platforms for contemporary vaccine design</article-title><source>Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.</source><year>2011</year><volume>3</volume><fpage>174</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1002/wnan.119</pub-id><pub-id pub-id-type="pmid">20872839</pub-id><pub-id pub-id-type="pmcid">PMC7169818</pub-id></element-citation></ref><ref id="B97-vaccines-04-00018"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lalibert&#233;-Gagn&#233;</surname><given-names>M.&#200;.</given-names></name><name name-style="western"><surname>Babin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bolduc</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gu&#233;rin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Drouin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Forget</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Majeau</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lapointe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Leclerc</surname><given-names>D.</given-names></name></person-group><article-title>Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP]</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>2535</fpage><lpage>2542</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.01.085</pub-id><pub-id pub-id-type="pmid">22326774</pub-id></element-citation></ref><ref id="B98-vaccines-04-00018"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okuno</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maehashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kerman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tamiya</surname><given-names>E.</given-names></name></person-group><article-title>Label-free immunosensor for prostate-specific antigen based on single-walled carbon nanotube array-modified microelectrodes</article-title><source>Biosens. Bioelectron.</source><year>2007</year><volume>22</volume><fpage>2377</fpage><lpage>2381</lpage><pub-id pub-id-type="doi">10.1016/j.bios.2006.09.038</pub-id><pub-id pub-id-type="pmid">17110096</pub-id></element-citation></ref><ref id="B99-vaccines-04-00018"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>G.</given-names></name></person-group><article-title>Enhanced mucosal and systemic immune responses obtained by porous silica nanoparticles used as an oral vaccine adjuvant: Effect of silica architecture on immunological properties</article-title><source>Int. J. Pharm.</source><year>2012</year><volume>436</volume><fpage>351</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2012.06.028</pub-id><pub-id pub-id-type="pmid">22721849</pub-id></element-citation></ref><ref id="B100-vaccines-04-00018"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>H.</given-names></name><name name-style="western"><surname>Maeyama</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Eto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoshihara</surname><given-names>S.</given-names></name></person-group><article-title>Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines</article-title><source>Vaccine</source><year>1993</year><volume>11</volume><fpage>914</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(93)90377-A</pub-id><pub-id pub-id-type="pmid">8212836</pub-id></element-citation></ref><ref id="B101-vaccines-04-00018"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aggerbeck</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fenger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Heron</surname><given-names>I.</given-names></name></person-group><article-title>Booster vaccination against diphtheria and tetanus in man. Comparison of calcium phosphate and aluminium hydroxide as adjuvants&#8212;II</article-title><source>Vaccine</source><year>1995</year><volume>13</volume><fpage>1366</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(94)00082-X</pub-id><pub-id pub-id-type="pmid">8585295</pub-id></element-citation></ref><ref id="B102-vaccines-04-00018"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morcol</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>S.J.</given-names></name></person-group><article-title>Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2</article-title><source>Clin. Diagn. Lab. Immunol.</source><year>2002</year><volume>9</volume><fpage>1021</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1128/CDLI.9.5.1021-1024.2002</pub-id><pub-id pub-id-type="pmid">12204953</pub-id><pub-id pub-id-type="pmcid">PMC120054</pub-id></element-citation></ref><ref id="B103-vaccines-04-00018"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Peek</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Power</surname><given-names>J.</given-names></name><name name-style="western"><surname>Markham</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yazzie</surname><given-names>B.</given-names></name><name name-style="western"><surname>Middaugh</surname><given-names>C.R.</given-names></name></person-group><article-title>Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><fpage>13406</fpage><lpage>13414</lpage><pub-id pub-id-type="doi">10.1074/jbc.M500687200</pub-id><pub-id pub-id-type="pmid">15684430</pub-id></element-citation></ref><ref id="B104-vaccines-04-00018"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>K.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tobery</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Ulmer</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Caulfield</surname><given-names>M.J.</given-names></name></person-group><article-title>Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate</article-title><source>Vaccine</source><year>2000</year><volume>18</volume><fpage>1227</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(99)00391-6</pub-id><pub-id pub-id-type="pmid">10649624</pub-id></element-citation></ref><ref id="B105-vaccines-04-00018"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ludwig</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>R.</given-names></name></person-group><article-title>Virus-like particles&#8212;universal molecular toolboxes</article-title><source>Curr. Opin. Biotechnol.</source><year>2007</year><volume>18</volume><fpage>537</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2007.10.013</pub-id><pub-id pub-id-type="pmid">18083549</pub-id><pub-id pub-id-type="pmcid">PMC7126091</pub-id></element-citation></ref><ref id="B106-vaccines-04-00018"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crawford</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Labbe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Burroughs</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Estes</surname><given-names>M.K.</given-names></name></person-group><article-title>Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells</article-title><source>J. Virol.</source><year>1994</year><volume>68</volume><fpage>5945</fpage><lpage>5952</lpage><pub-id pub-id-type="pmid">8057471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.68.9.5945-5952.1994</pub-id><pub-id pub-id-type="pmcid">PMC237000</pub-id></element-citation></ref><ref id="B107-vaccines-04-00018"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Storni</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ruedl</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schwendener</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Renner</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>M.F.</given-names></name></person-group><article-title>Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects</article-title><source>J. Immunol.</source><year>2004</year><volume>172</volume><fpage>1777</fpage><lpage>1785</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.3.1777</pub-id><pub-id pub-id-type="pmid">14734761</pub-id></element-citation></ref><ref id="B108-vaccines-04-00018"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gah&#233;ry-S&#233;gard</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pialoux</surname><given-names>G.</given-names></name><name name-style="western"><surname>Charmeteau</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sermet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Poncelet</surname><given-names>H.</given-names></name><name name-style="western"><surname>Raux</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tartar</surname><given-names>A.</given-names></name><name name-style="western"><surname>L&#233;vy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Gras-Masse</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guillet</surname><given-names>J.G.</given-names></name></person-group><article-title>Multiepitopic B-and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine</article-title><source>J. Virol.</source><year>2000</year><volume>74</volume><fpage>1694</fpage><lpage>1703</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.4.1694-1703.2000</pub-id><pub-id pub-id-type="pmid">10644339</pub-id><pub-id pub-id-type="pmcid">PMC111644</pub-id></element-citation></ref><ref id="B109-vaccines-04-00018"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klinguer</surname><given-names>C.</given-names></name><name name-style="western"><surname>David</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kouach</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wieruszeski</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Tartar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marzin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Gras-Masse</surname><given-names>H.</given-names></name></person-group><article-title>Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidate</article-title><source>Vaccine</source><year>1999</year><volume>18</volume><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(99)00196-6</pub-id><pub-id pub-id-type="pmid">10506650</pub-id></element-citation></ref><ref id="B110-vaccines-04-00018"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>BenMohamed</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wechsler</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Nesburn</surname><given-names>A.B.</given-names></name></person-group><article-title>Lipopeptide vaccines&#8212;yesterday, today, and tomorrow</article-title><source>Lancet Infect. Dis.</source><year>2002</year><volume>2</volume><fpage>425</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(02)00318-3</pub-id><pub-id pub-id-type="pmid">12127354</pub-id></element-citation></ref><ref id="B111-vaccines-04-00018"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minigo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Scholzen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Kalkanidis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pietersz</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Apostolopoulos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Plebanski</surname><given-names>M.</given-names></name></person-group><article-title>Poly-l-lysine-coated nanoparticles: A potent delivery system to enhance DNA vaccine efficacy</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>1316</fpage><lpage>1327</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.09.086</pub-id><pub-id pub-id-type="pmid">17052812</pub-id></element-citation></ref><ref id="B112-vaccines-04-00018"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Locher</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Putnam</surname><given-names>D.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Witt</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ashlock</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>J.A.</given-names></name></person-group><article-title>Enhancement of a human immunodeficiency virus env DNA vaccine using a novel polycationic nanoparticle formulation</article-title><source>Immunol. Lett.</source><year>2003</year><volume>90</volume><fpage>67</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2003.02.001</pub-id><pub-id pub-id-type="pmid">14687705</pub-id></element-citation></ref><ref id="B113-vaccines-04-00018"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>F.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>D.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C.</given-names></name></person-group><article-title>Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice</article-title><source>J. Gene Med.</source><year>2007</year><volume>9</volume><fpage>253</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1002/jgm.1017</pub-id><pub-id pub-id-type="pmid">17397104</pub-id></element-citation></ref><ref id="B114-vaccines-04-00018"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gamazo</surname><given-names>C.</given-names></name><name name-style="western"><surname>San Roman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sanz</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Espuelas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Irache</surname><given-names>J.M.</given-names></name></person-group><article-title>Allergen immunotherapy with nanoparticles containing lipopolysaccharide from <italic toggle="yes">Brucella ovis</italic></article-title><source>Eur. J. Pharm. Biopharm.</source><year>2008</year><volume>70</volume><fpage>711</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2008.05.016</pub-id><pub-id pub-id-type="pmid">18582571</pub-id></element-citation></ref><ref id="B115-vaccines-04-00018"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Persing</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Coler</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Lacy</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Baldridge</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Hershberg</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name></person-group><article-title>Taking toll: Lipid A mimetics as adjuvants and immunomodulators</article-title><source>Trends Microbiol.</source><year>2002</year><volume>10</volume><fpage>32</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/S0966-842X(02)02426-5</pub-id><pub-id pub-id-type="pmid">12377566</pub-id></element-citation></ref><ref id="B116-vaccines-04-00018"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>A.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>The use of layered double hydroxides as DNA vaccine delivery vector for enhancement of anti-melanoma immune response</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><fpage>469</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2010.08.107</pub-id><pub-id pub-id-type="pmid">20934217</pub-id></element-citation></ref><ref id="B117-vaccines-04-00018"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pathak</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Marrache</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harn</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title>Mito-DCA: A mitochondria targeted molecular scaffold for efficacious delivery of metabolic modulator dichloroacetate</article-title><source>ACS Chem. Biol.</source><year>2014</year><volume>9</volume><fpage>1178</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1021/cb400944y</pub-id><pub-id pub-id-type="pmid">24617941</pub-id><pub-id pub-id-type="pmcid">PMC4033660</pub-id></element-citation></ref><ref id="B118-vaccines-04-00018"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biswas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dodwadkar</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Sawant</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Koshkaryev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Torchilin</surname><given-names>V.P.</given-names></name></person-group><article-title>Surface modification of liposomes with rhodamine-123-conjugated polymer results in enhanced mitochondrial targeting</article-title><source>J. Drug Target.</source><year>2011</year><volume>19</volume><fpage>552</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.3109/1061186X.2010.536983</pub-id><pub-id pub-id-type="pmid">21348804</pub-id><pub-id pub-id-type="pmcid">PMC3492939</pub-id></element-citation></ref><ref id="B119-vaccines-04-00018"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Midgley</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>C.</given-names></name></person-group><article-title>The role of mitochondria in the uptake of methyltriphenylphosphonium ion by Saccharomyces cerevisiae</article-title><source>FEMS Microbiol. Lett.</source><year>1985</year><volume>26</volume><fpage>311</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.1985.tb01617.x</pub-id></element-citation></ref><ref id="B120-vaccines-04-00018"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>M.P.</given-names></name></person-group><article-title>Targeting lipophilic cations to mitochondria</article-title><source>Biochim. Biophys. Acta</source><year>2008</year><volume>1777</volume><fpage>1028</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1016/j.bbabio.2008.03.029</pub-id><pub-id pub-id-type="pmid">18439417</pub-id></element-citation></ref><ref id="B121-vaccines-04-00018"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.R.</given-names></name></person-group><article-title>New insights of transmembranal mechanism and subcellular localization of noncovalently modified single-walled carbon nanotubes</article-title><source>Nano Lett.</source><year>2010</year><volume>10</volume><fpage>1677</fpage><lpage>1681</lpage><pub-id pub-id-type="doi">10.1021/nl100004m</pub-id><pub-id pub-id-type="pmid">20369892</pub-id><pub-id pub-id-type="pmcid">PMC6005367</pub-id></element-citation></ref><ref id="B122-vaccines-04-00018"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.B.</given-names></name></person-group><article-title>Mitochondrial membrane potential in living cells</article-title><source>Annu. Rev. Cell Biol.</source><year>1988</year><volume>4</volume><fpage>155</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1146/annurev.cb.04.110188.001103</pub-id><pub-id pub-id-type="pmid">3058159</pub-id></element-citation></ref><ref id="B123-vaccines-04-00018"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Appleby</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Porteous</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>G.</given-names></name><name name-style="western"><surname>James</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Shannon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>M.P.</given-names></name></person-group><article-title>Quantitation and origin of the mitochondrial membrane potential in human cells lacking mitochondrial DNA</article-title><source>Eur. J. Biochem.</source><year>1999</year><volume>262</volume><fpage>108</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1046/j.1432-1327.1999.00350.x</pub-id><pub-id pub-id-type="pmid">10231371</pub-id></element-citation></ref><ref id="B124-vaccines-04-00018"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider Berlin</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Ammini</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>T.C.</given-names></name></person-group><article-title>Dequalinium induces a selective depletion of mitochondrial DNA from HeLa human cervical carcinoma cells</article-title><source>Exp. Cell Res.</source><year>1998</year><volume>245</volume><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1006/excr.1998.4236</pub-id><pub-id pub-id-type="pmid">9828109</pub-id></element-citation></ref><ref id="B125-vaccines-04-00018"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weissig</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lizano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Torchilin</surname><given-names>V.P.</given-names></name></person-group><article-title>Micellar delivery system for dequalinium-A lipophilic cationic drug with anticarcinoma activity</article-title><source>J. Liposome Res.</source><year>1998</year><volume>8</volume><fpage>391</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.3109/08982109809035542</pub-id></element-citation></ref><ref id="B126-vaccines-04-00018"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W.L.</given-names></name></person-group><article-title>The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><fpage>5673</fpage><lpage>5687</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.04.029</pub-id><pub-id pub-id-type="pmid">21550109</pub-id></element-citation></ref><ref id="B127-vaccines-04-00018"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deocaris</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Widodo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shrestha</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ohtaka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamasaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kaul</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Wadhwa</surname><given-names>R.</given-names></name></person-group><article-title>Mortalin sensitizes human cancer cells to MKT-077-induced senescence</article-title><source>Cancer Lett.</source><year>2007</year><volume>252</volume><fpage>259</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2006.12.038</pub-id><pub-id pub-id-type="pmid">17306926</pub-id></element-citation></ref><ref id="B128-vaccines-04-00018"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fantin</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Leder</surname><given-names>P.</given-names></name></person-group><article-title>F16, a mitochondriotoxic compound, triggers apoptosis or necrosis depending on the genetic background of the target carcinoma cell</article-title><source>Cancer Res.</source><year>2004</year><volume>64</volume><fpage>329</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-0899</pub-id><pub-id pub-id-type="pmid">14729642</pub-id></element-citation></ref><ref id="B129-vaccines-04-00018"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Z.D.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Synthesis of F16 conjugated with 5-fluorouracil and biophysical investigation of its interaction with bovine serum albumin by a spectroscopic and molecular modeling approach</article-title><source>Luminescence</source><year>2013</year><volume>28</volume><fpage>865</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1002/bio.2447</pub-id><pub-id pub-id-type="pmid">23161820</pub-id></element-citation></ref><ref id="B130-vaccines-04-00018"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hickey</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Ruhayel</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Berners-Price</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Filipovska</surname><given-names>A.</given-names></name></person-group><article-title>Mitochondria-targeted chemotherapeutics: The rational design of gold (I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols</article-title><source>J. Am. Chem. Soc.</source><year>2008</year><volume>130</volume><fpage>12570</fpage><lpage>12571</lpage><pub-id pub-id-type="doi">10.1021/ja804027j</pub-id><pub-id pub-id-type="pmid">18729360</pub-id></element-citation></ref><ref id="B131-vaccines-04-00018"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrache</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title>Formulation and optimization of mitochondria-targeted polymeric nanoparticles</article-title><source>Methods Mol. Biol.</source><year>2015</year><volume>2</volume><fpage>103</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">25634270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-2288-8_8</pub-id></element-citation></ref><ref id="B132-vaccines-04-00018"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrache</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title>Detouring of cisplatin to access mitochondrial genome for overcoming resistance</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>10444</fpage><lpage>10449</lpage><pub-id pub-id-type="doi">10.1073/pnas.1405244111</pub-id><pub-id pub-id-type="pmid">25002500</pub-id><pub-id pub-id-type="pmcid">PMC4115573</pub-id></element-citation></ref><ref id="B133-vaccines-04-00018"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldhaeusser</surname><given-names>B.</given-names></name><name name-style="western"><surname>Platt</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Marrache</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kolishetti</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Reno</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Howerth</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title>Evaluation of nanoparticle delivered cisplatin in beagles</article-title><source>Nanoscale</source><year>2015</year><volume>7</volume><fpage>13822</fpage><lpage>13830</lpage><pub-id pub-id-type="doi">10.1039/C5NR03447G</pub-id><pub-id pub-id-type="pmid">26234400</pub-id></element-citation></ref><ref id="B134-vaccines-04-00018"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pathak</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title>A Nanoparticle Cocktail: Temporal Release of Predefined Drug Combinations</article-title><source>J. Am. Chem. Soc.</source><year>2015</year><volume>137</volume><fpage>8324</fpage><lpage>8327</lpage><pub-id pub-id-type="doi">10.1021/jacs.5b03078</pub-id><pub-id pub-id-type="pmid">26086212</pub-id></element-citation></ref><ref id="B135-vaccines-04-00018"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalathil</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Banik</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ruiter</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title>New formulation of old aspirin for better delivery</article-title><source>Chem. Commun.</source><year>2016</year><volume>52</volume><fpage>140</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1039/C5CC07316B</pub-id><pub-id pub-id-type="pmid">26503669</pub-id><pub-id pub-id-type="pmcid">PMC4679634</pub-id></element-citation></ref><ref id="B136-vaccines-04-00018"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrache</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title>The energy blocker inside the power house: Mitochondria targeted delivery of 3-bromopyruvate</article-title><source>Chem. Sci.</source><year>2015</year><volume>6</volume><fpage>1832</fpage><lpage>1845</lpage><pub-id pub-id-type="doi">10.1039/C4SC01963F</pub-id><pub-id pub-id-type="pmid">25709804</pub-id><pub-id pub-id-type="pmcid">PMC4335358</pub-id></element-citation></ref><ref id="B137-vaccines-04-00018"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrache</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title>Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>9445</fpage><lpage>9450</lpage><pub-id pub-id-type="doi">10.1073/pnas.1301929110</pub-id><pub-id pub-id-type="pmid">23671083</pub-id><pub-id pub-id-type="pmcid">PMC3677461</pub-id></element-citation></ref><ref id="B138-vaccines-04-00018"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omura</surname><given-names>T.</given-names></name></person-group><article-title>Mitochondria-targeting sequence, a multi-role sorting sequence recognized at all steps of protein import into mitochondria</article-title><source>J. Biochem.</source><year>1998</year><volume>123</volume><fpage>1010</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a022036</pub-id><pub-id pub-id-type="pmid">9603986</pub-id></element-citation></ref><ref id="B139-vaccines-04-00018"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neupert</surname><given-names>W.</given-names></name></person-group><article-title>Protein import into mitochondria</article-title><source>Annu. Rev. Biochem.</source><year>1997</year><volume>66</volume><fpage>863</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.66.1.863</pub-id><pub-id pub-id-type="pmid">9242927</pub-id></element-citation></ref><ref id="B140-vaccines-04-00018"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalafut</surname><given-names>D.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Chmielewski</surname><given-names>J.</given-names></name></person-group><article-title>Mitochondrial targeting of a cationic amphiphilic polyproline helix</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2012</year><volume>22</volume><fpage>561</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2011.10.077</pub-id><pub-id pub-id-type="pmid">22130131</pub-id></element-citation></ref><ref id="B141-vaccines-04-00018"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Heijne</surname><given-names>G.</given-names></name></person-group><article-title>Mitochondrial targeting sequences may form amphiphilic helices</article-title><source>EMBO J.</source><year>1986</year><volume>5</volume><fpage>1335</fpage><lpage>1342</lpage><pub-id pub-id-type="pmid">3015599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1460-2075.1986.tb04364.x</pub-id><pub-id pub-id-type="pmcid">PMC1166945</pub-id></element-citation></ref><ref id="B142-vaccines-04-00018"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yousif</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>S.O.</given-names></name></person-group><article-title>Targeting Mitochondria with Organelle-Specific Compounds: Strategies and Applications</article-title><source>ChemBioChem</source><year>2009</year><volume>10</volume><fpage>1939</fpage><lpage>1950</lpage><pub-id pub-id-type="doi">10.1002/cbic.200900185</pub-id><pub-id pub-id-type="pmid">19637148</pub-id></element-citation></ref><ref id="B143-vaccines-04-00018"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Met&#243;n</surname><given-names>I.</given-names></name><name name-style="western"><surname>Egea</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Eraso</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Baanante</surname><given-names>I.V.</given-names></name></person-group><article-title>The N-terminal sequence directs import of mitochondrial alanine aminotransferase into mitochondria</article-title><source>FEBS Lett.</source><year>2004</year><volume>566</volume><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2004.04.051</pub-id><pub-id pub-id-type="pmid">15147904</pub-id></element-citation></ref><ref id="B144-vaccines-04-00018"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shokolenko</surname><given-names>I.N.</given-names></name><name name-style="western"><surname>Alexeyev</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>LeDoux</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>G.L.</given-names></name></person-group><article-title>TAT-mediated protein transduction and targeted delivery of fusion proteins into mitochondria of breast cancer cells</article-title><source>DNA Repair</source><year>2005</year><volume>4</volume><fpage>511</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2004.11.009</pub-id><pub-id pub-id-type="pmid">15725631</pub-id></element-citation></ref><ref id="B145-vaccines-04-00018"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takaya</surname><given-names>K.</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kitamoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Arioka</surname><given-names>M.</given-names></name></person-group><article-title>A cytosolic phospholipase A2-like protein in the filamentous fungus Aspergillus oryzae localizes to the intramembrane space of the mitochondria</article-title><source>FEMS Microbiol. Lett.</source><year>2009</year><volume>301</volume><fpage>201</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.2009.01818.x</pub-id><pub-id pub-id-type="pmid">19889028</pub-id></element-citation></ref><ref id="B146-vaccines-04-00018"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchenko</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Zaika</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moll</surname><given-names>U.M.</given-names></name></person-group><article-title>Death signal-induced localization of p53 protein to mitochondria a potential role in apoptotic signaling</article-title><source>J. Biol. Chem.</source><year>2000</year><volume>275</volume><fpage>16202</fpage><lpage>16212</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.21.16202</pub-id><pub-id pub-id-type="pmid">10821866</pub-id></element-citation></ref><ref id="B147-vaccines-04-00018"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Soong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Birk</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Schiller</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Szeto</surname><given-names>H.H.</given-names></name></person-group><article-title>Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>34682</fpage><lpage>34690</lpage><pub-id pub-id-type="doi">10.1074/jbc.M402999200</pub-id><pub-id pub-id-type="pmid">15178689</pub-id></element-citation></ref><ref id="B148-vaccines-04-00018"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Stauffer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Szeto</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Suthanthiran</surname><given-names>M.</given-names></name></person-group><article-title>Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function</article-title><source>J. Am. Soc. Nephrol.</source><year>2007</year><volume>18</volume><fpage>213</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1681/ASN.2006080825</pub-id><pub-id pub-id-type="pmid">17151329</pub-id></element-citation></ref><ref id="B149-vaccines-04-00018"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rivera-S&#225;nchez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ayala-Pe&#241;a</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Budworth</surname><given-names>H.</given-names></name><name name-style="western"><surname>Skoda</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Niedernhofer</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Wipf</surname><given-names>P.</given-names></name><name name-style="western"><surname>McMurray</surname><given-names>C.T.</given-names></name></person-group><article-title>Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of huntington&#8217;s disease</article-title><source>Cell Rep.</source><year>2012</year><volume>2</volume><fpage>1137</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2012.10.001</pub-id><pub-id pub-id-type="pmid">23122961</pub-id><pub-id pub-id-type="pmcid">PMC3513647</pub-id></element-citation></ref><ref id="B150-vaccines-04-00018"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wipf</surname><given-names>P.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Belikova</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Tyurin</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Fink</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Kagan</surname><given-names>V.E.</given-names></name></person-group><article-title>Mitochondrial targeting of selective electron scavengers: Synthesis and biological analysis of hemigramicidin-TEMPO conjugates</article-title><source>J. Am. Chem. Soc.</source><year>2005</year><volume>127</volume><fpage>12460</fpage><lpage>12461</lpage><pub-id pub-id-type="doi">10.1021/ja053679l</pub-id><pub-id pub-id-type="pmid">16144372</pub-id></element-citation></ref><ref id="B151-vaccines-04-00018"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Belikova</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Hoye</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Epperly</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Greenberger</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Wipf</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kagan</surname><given-names>V.E.</given-names></name></person-group><article-title>A mitochondria-targeted nitroxide/hemigramicidin S conjugate protects mouse embryonic cells against gamma irradiation</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2008</year><volume>70</volume><fpage>816</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2007.10.047</pub-id><pub-id pub-id-type="pmid">18262096</pub-id><pub-id pub-id-type="pmcid">PMC2527544</pub-id></element-citation></ref><ref id="B152-vaccines-04-00018"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robin</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Anandatheerthavarada</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Cudic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Otvos</surname><given-names>L.</given-names></name><name name-style="western"><surname>Avadhani</surname><given-names>N.G.</given-names></name></person-group><article-title>Mitochondrial targeted cytochrome P450 2E1 (P450 MT5) contains an intact N terminus and requires mitochondrial specific electron transfer proteins for activity</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>24680</fpage><lpage>24689</lpage><pub-id pub-id-type="doi">10.1074/jbc.M100363200</pub-id><pub-id pub-id-type="pmid">11325963</pub-id></element-citation></ref><ref id="B153-vaccines-04-00018"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nargund</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Pellegrino</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Fiorese</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>C.M.</given-names></name></person-group><article-title>Mitochondrial import efficiency of ATFS-1 regulates mitochondrial UPR activation</article-title><source>Science</source><year>2012</year><volume>337</volume><fpage>587</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1126/science.1223560</pub-id><pub-id pub-id-type="pmid">22700657</pub-id><pub-id pub-id-type="pmcid">PMC3518298</pub-id></element-citation></ref><ref id="B154-vaccines-04-00018"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name></person-group><article-title>Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response</article-title><source>Biomaterials</source><year>2015</year><volume>52</volume><fpage>126</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2015.02.004</pub-id><pub-id pub-id-type="pmid">25818419</pub-id></element-citation></ref><ref id="B155-vaccines-04-00018"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakase</surname><given-names>I.</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Katayama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hirose</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pujals</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Arakawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Futaki</surname><given-names>S.</given-names></name></person-group><article-title>Transformation of an antimicrobial peptide into a plasma membrane-permeable, mitochondria-targeted peptide via the substitution of lysine with arginine</article-title><source>Chem. Commun.</source><year>2012</year><volume>48</volume><fpage>11097</fpage><lpage>11099</lpage><pub-id pub-id-type="doi">10.1039/c2cc35872g</pub-id><pub-id pub-id-type="pmid">23038156</pub-id></element-citation></ref><ref id="B156-vaccines-04-00018"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Drew</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Sallam</surname><given-names>T.</given-names></name><name name-style="western"><surname>Martin-Montalvo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hevener</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>de Cabo</surname><given-names>R.</given-names></name><etal/></person-group><article-title>The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance</article-title><source>Cell Metab.</source><year>2015</year><volume>21</volume><fpage>443</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2015.02.009</pub-id><pub-id pub-id-type="pmid">25738459</pub-id><pub-id pub-id-type="pmcid">PMC4350682</pub-id></element-citation></ref><ref id="B157-vaccines-04-00018"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flierl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cottrell</surname><given-names>B.</given-names></name><name name-style="western"><surname>Murdock</surname><given-names>D.</given-names></name><name name-style="western"><surname>Seibel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>D.C.</given-names></name></person-group><article-title>Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid</article-title><source>Mol. Ther.</source><year>2003</year><volume>7</volume><fpage>550</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/S1525-0016(03)00037-6</pub-id><pub-id pub-id-type="pmid">12727119</pub-id></element-citation></ref><ref id="B158-vaccines-04-00018"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horton</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>S.O.</given-names></name></person-group><article-title>Mitochondria-penetrating peptides</article-title><source>Chem. Biol.</source><year>2008</year><volume>15</volume><fpage>375</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2008.03.015</pub-id><pub-id pub-id-type="pmid">18420144</pub-id></element-citation></ref><ref id="B159-vaccines-04-00018"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawamura</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yasuzaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H.</given-names></name></person-group><article-title>Intracellular observation of nanocarriers modified with a mitochondrial targeting signal peptide</article-title><source>J. Biosci. Bioeng.</source><year>2013</year><volume>116</volume><fpage>634</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1016/j.jbiosc.2013.05.001</pub-id><pub-id pub-id-type="pmid">23735326</pub-id></element-citation></ref><ref id="B160-vaccines-04-00018"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H.</given-names></name></person-group><article-title>Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier</article-title><source>Mitochondrion</source><year>2013</year><volume>13</volume><fpage>526</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1016/j.mito.2012.09.001</pub-id><pub-id pub-id-type="pmid">23000575</pub-id></element-citation></ref><ref id="B161-vaccines-04-00018"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shedlock</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H.</given-names></name></person-group><article-title>Requirement for CD4 T cell help in generating functional CD8 T cell memory</article-title><source>Science</source><year>2003</year><volume>300</volume><fpage>337</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1126/science.1082305</pub-id><pub-id pub-id-type="pmid">12690201</pub-id></element-citation></ref><ref id="B162-vaccines-04-00018"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brossart</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wirths</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brugger</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kanz</surname><given-names>L.</given-names></name></person-group><article-title>Dendritic cells in cancer vaccines</article-title><source>Exp. Hematol.</source><year>2001</year><volume>29</volume><fpage>1247</fpage><lpage>1255</lpage><pub-id pub-id-type="doi">10.1016/S0301-472X(01)00730-5</pub-id><pub-id pub-id-type="pmid">11698120</pub-id></element-citation></ref><ref id="B163-vaccines-04-00018"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banchereau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>R.M.</given-names></name></person-group><article-title>Dendritic cells and the control of immunity</article-title><source>Nature</source><year>1998</year><volume>392</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1038/32588</pub-id><pub-id pub-id-type="pmid">9521319</pub-id></element-citation></ref><ref id="B164-vaccines-04-00018"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valitutti</surname><given-names>S.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cella</surname><given-names>M.</given-names></name><name name-style="western"><surname>Padovan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lanzavecchia</surname><given-names>A.</given-names></name></person-group><article-title>Serial triggering of many T-cell receptors by a few peptide MHC complexes</article-title><source>Nature</source><year>1995</year><volume>375</volume><fpage>148</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1038/375148a0</pub-id><pub-id pub-id-type="pmid">7753171</pub-id></element-citation></ref><ref id="B165-vaccines-04-00018"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>J.</given-names></name></person-group><article-title>Advances in dendritic cell-based vaccine of cancer</article-title><source>Cancer Biother. Radiopharm.</source><year>2002</year><volume>17</volume><fpage>601</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1089/108497802320970217</pub-id><pub-id pub-id-type="pmid">12537664</pub-id></element-citation></ref><ref id="B166-vaccines-04-00018"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinman</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Banchereau</surname><given-names>J.</given-names></name></person-group><article-title>Taking dendritic cells into medicine</article-title><source>Nature</source><year>2007</year><volume>449</volume><fpage>419</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1038/nature06175</pub-id><pub-id pub-id-type="pmid">17898760</pub-id></element-citation></ref><ref id="B167-vaccines-04-00018"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butterfield</surname><given-names>L.H.</given-names></name></person-group><article-title>Dendritic cells in cancer immunotherapy clinical trials: Are we making progress?</article-title><source>Front. Immunol.</source><year>2013</year><pub-id pub-id-type="doi">10.3389/fimmu.2013.00454</pub-id><pub-id pub-id-type="pmid">24379816</pub-id><pub-id pub-id-type="pmcid">PMC3861778</pub-id></element-citation></ref><ref id="B168-vaccines-04-00018"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregoire</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ligeza-Poisson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Juge-Morineau</surname><given-names>N.</given-names></name><name name-style="western"><surname>Spisek</surname><given-names>R.</given-names></name></person-group><article-title>Anti-cancer therapy using dendritic cells and apoptotic tumour cells: Pre-clinical data in human mesothelioma and acute myeloid leukaemia</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>791</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00600-X</pub-id><pub-id pub-id-type="pmid">12531361</pub-id></element-citation></ref><ref id="B169-vaccines-04-00018"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Figdor</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Lesterhuis</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Melief</surname><given-names>C.J.</given-names></name></person-group><article-title>Dendritic cell immunotherapy: Mapping the way</article-title><source>Nat. Med.</source><year>2004</year><volume>10</volume><fpage>475</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1038/nm1039</pub-id><pub-id pub-id-type="pmid">15122249</pub-id></element-citation></ref><ref id="B170-vaccines-04-00018"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lanzavecchia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sallusto</surname><given-names>F.</given-names></name></person-group><article-title>Regulation of T cell immunity by dendritic cells</article-title><source>Cell</source><year>2001</year><volume>106</volume><fpage>263</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00455-X</pub-id><pub-id pub-id-type="pmid">11509174</pub-id></element-citation></ref><ref id="B171-vaccines-04-00018"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayordomo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zorina</surname><given-names>T.</given-names></name><name name-style="western"><surname>Storkus</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zitvogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Celluzzi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Falo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Melief</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ildstad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kast</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Deleo</surname><given-names>A.</given-names></name></person-group><article-title>Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity</article-title><source>Nat. Med.</source><year>1995</year><volume>1</volume><fpage>1297</fpage><lpage>1302</lpage><pub-id pub-id-type="doi">10.1038/nm1295-1297</pub-id><pub-id pub-id-type="pmid">7489412</pub-id></element-citation></ref><ref id="B172-vaccines-04-00018"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahma</surname><given-names>O.E.</given-names></name><name name-style="western"><surname>Herrin</surname><given-names>V.E.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Toubaji</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dakheel</surname><given-names>O.</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Abu</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Mkrtichyan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Berzofsky</surname><given-names>J.A.</given-names></name></person-group><article-title>Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer</article-title><source>J. Transl. Med.</source><year>2014</year><volume>12</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12967-014-0353-4</pub-id><pub-id pub-id-type="pmid">25510844</pub-id><pub-id pub-id-type="pmcid">PMC4269078</pub-id></element-citation></ref><ref id="B173-vaccines-04-00018"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>T.</given-names></name></person-group><article-title>A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer</article-title><source>Clin. Exp. Med.</source><year>2012</year><volume>12</volume><fpage>173</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1007/s10238-011-0159-0</pub-id><pub-id pub-id-type="pmid">21932124</pub-id></element-citation></ref><ref id="B174-vaccines-04-00018"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phuphanich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Rudnick</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Mazer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nuno</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>R.M.</given-names></name></person-group><article-title>Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma</article-title><source>Cancer Immunol. Immunother.</source><year>2013</year><volume>62</volume><fpage>125</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1007/s00262-012-1319-0</pub-id><pub-id pub-id-type="pmid">22847020</pub-id><pub-id pub-id-type="pmcid">PMC3541928</pub-id></element-citation></ref><ref id="B175-vaccines-04-00018"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamayo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Irache</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Mansilla</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ochoa-Rep&#225;raz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lasarte</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Gamazo</surname><given-names>C.</given-names></name></person-group><article-title>Poly (anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation</article-title><source>Clin. Vaccine Immunol.</source><year>2010</year><volume>17</volume><fpage>1356</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1128/CVI.00164-10</pub-id><pub-id pub-id-type="pmid">20631332</pub-id><pub-id pub-id-type="pmcid">PMC2944445</pub-id></element-citation></ref><ref id="B176-vaccines-04-00018"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clements</surname><given-names>C.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>E.</given-names></name></person-group><article-title>The global impact of vaccines containing aluminium adjuvants</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00168-8</pub-id><pub-id pub-id-type="pmid">12184361</pub-id></element-citation></ref><ref id="B177-vaccines-04-00018"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.M.</given-names></name></person-group><article-title>Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response</article-title><source>Nat. Nanotechnol.</source><year>2011</year><volume>6</volume><fpage>645</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1038/nnano.2011.153</pub-id><pub-id pub-id-type="pmid">21926980</pub-id><pub-id pub-id-type="pmcid">PMC3483867</pub-id></element-citation></ref><ref id="B178-vaccines-04-00018"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamblin</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>T.</given-names></name></person-group><article-title>Photodynamic therapy: A new antimicrobial approach to infectious disease?</article-title><source>Photochem. Photobiol. Sci.</source><year>2004</year><volume>3</volume><fpage>436</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1039/b311900a</pub-id><pub-id pub-id-type="pmid">15122361</pub-id><pub-id pub-id-type="pmcid">PMC3071049</pub-id></element-citation></ref><ref id="B179-vaccines-04-00018"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juarranz</surname><given-names>&#193;.</given-names></name><name name-style="western"><surname>Ja&#233;n</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sanz-Rodr&#237;guez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cuevas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>S.</given-names></name></person-group><article-title>Photodynamic therapy of cancer. Basic principles and applications</article-title><source>Clin. Transl. Onco.</source><year>2008</year><volume>10</volume><fpage>148</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1007/s12094-008-0172-2</pub-id><pub-id pub-id-type="pmid">18321817</pub-id></element-citation></ref><ref id="B180-vaccines-04-00018"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Triesscheijn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schellens</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>F.A.</given-names></name></person-group><article-title>Photodynamic therapy in oncology</article-title><source>Oncologist</source><year>2006</year><volume>11</volume><fpage>1034</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.11-9-1034</pub-id><pub-id pub-id-type="pmid">17030646</pub-id></element-citation></ref><ref id="B181-vaccines-04-00018"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pozzi</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Maciaszek</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Rock</surname><given-names>K.L.</given-names></name></person-group><article-title>Both dendritic cells and macrophages can stimulate naive CD8 T cells <italic toggle="yes">in vivo</italic> to proliferate, develop effector function, and differentiate into memory cells</article-title><source>J. Immunol.</source><year>2005</year><volume>175</volume><fpage>2071</fpage><lpage>2081</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.175.4.2071</pub-id><pub-id pub-id-type="pmid">16081773</pub-id></element-citation></ref><ref id="B182-vaccines-04-00018"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fievez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Plapied</surname><given-names>L.</given-names></name><name name-style="western"><surname>des Rieux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pourcelle</surname><given-names>V.</given-names></name><name name-style="western"><surname>Freichels</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wascotte</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vanderhaeghen</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Jer&#244;me</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vanderplasschen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marchand-Brynaert</surname><given-names>J.</given-names></name></person-group><article-title>Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2009</year><volume>73</volume><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2009.04.009</pub-id><pub-id pub-id-type="pmid">19409989</pub-id></element-citation></ref><ref id="B183-vaccines-04-00018"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nycholat</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pilotte</surname><given-names>J.</given-names></name><name name-style="western"><surname>Crocker</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Paulson</surname><given-names>J.C.</given-names></name></person-group><article-title>Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0039039</pub-id><pub-id pub-id-type="pmid">22723922</pub-id><pub-id pub-id-type="pmcid">PMC3378521</pub-id></element-citation></ref><ref id="B184-vaccines-04-00018"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>T.</given-names></name></person-group><article-title>The interactions between pristine graphene and macrophages and the production of cytokines/chemokines via TLR-and NF-&#954;B-related signaling pathways</article-title><source>Biomaterials</source><year>2012</year><volume>33</volume><fpage>6933</fpage><lpage>6942</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.06.064</pub-id><pub-id pub-id-type="pmid">22796167</pub-id></element-citation></ref><ref id="B185-vaccines-04-00018"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thurber</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>C.</given-names></name><name name-style="western"><surname>Punnoose</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wingett</surname><given-names>D.</given-names></name></person-group><article-title>The Influences of Cell Type and ZnO Nanoparticle Size on Immune Cell Cytotoxicity and Cytokine Induction</article-title><source>Nanoscale Res. Lett.</source><year>2009</year><volume>4</volume><fpage>1409</fpage><lpage>1420</lpage><pub-id pub-id-type="doi">10.1007/s11671-009-9413-8</pub-id><pub-id pub-id-type="pmid">20652105</pub-id><pub-id pub-id-type="pmcid">PMC2894345</pub-id></element-citation></ref><ref id="B186-vaccines-04-00018"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Das</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dwivedi</surname><given-names>P.D.</given-names></name></person-group><article-title>Cytotoxicity and uptake of zinc oxide nanoparticles leading to enhanced inflammatory cytokines levels in murine macrophages: Comparison with bulk zinc oxide</article-title><source>J. Biomed. Nanotechnol.</source><year>2011</year><volume>7</volume><fpage>110</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1166/jbn.2011.1226</pub-id><pub-id pub-id-type="pmid">21485828</pub-id></element-citation></ref><ref id="B187-vaccines-04-00018"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The effect of Gd@C<sub>82</sub>(OH)<sub>22</sub> nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-&#945; mediated cellular immunity</article-title><source>Biomaterials</source><year>2009</year><volume>30</volume><fpage>3934</fpage><lpage>3945</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2009.04.001</pub-id><pub-id pub-id-type="pmid">19403166</pub-id></element-citation></ref><ref id="B188-vaccines-04-00018"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name></person-group><article-title>Polyvinylpyrrolidone-poly (ethylene glycol) modified silver nanorods can be a safe, noncarrier adjuvant for HIV vaccine</article-title><source>ACS Nano</source><year>2016</year><volume>10</volume><fpage>3589</fpage><lpage>3596</lpage><pub-id pub-id-type="doi">10.1021/acsnano.5b08025</pub-id><pub-id pub-id-type="pmid">26844372</pub-id></element-citation></ref><ref id="B189-vaccines-04-00018"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parry</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Clemson</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bernhard</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>N.R.</given-names></name></person-group><article-title>Multicopy multivalent&#8217; glycopolymer-stabilized gold nanoparticles as potential synthetic cancer vaccines</article-title><source>J. Am. Chem. Soc.</source><year>2013</year><volume>135</volume><fpage>9362</fpage><lpage>9365</lpage><pub-id pub-id-type="doi">10.1021/ja4046857</pub-id><pub-id pub-id-type="pmid">23763610</pub-id><pub-id pub-id-type="pmcid">PMC3928990</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="vaccines-04-00018-f001" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Overview of possible vaccines that can be generated using NPs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-04-00018-g001.jpg"/></fig><fig id="vaccines-04-00018-f002" position="float" orientation="portrait"><label>Figure 2</label><caption><p>The schematic diagram of action of mitochondria targeted ZnPc NPs. Redrawn from Reference [<xref rid="B21-vaccines-04-00018" ref-type="bibr">21</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-04-00018-g002.jpg"/></fig><table-wrap id="vaccines-04-00018-t001" position="float" orientation="portrait"><object-id pub-id-type="pii">vaccines-04-00018-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of possible mitochondrial targets for vaccine development.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Possible targets</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immune response</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Possible Application</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dendritic cell (DC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitochondrial DNA (mtDNA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induces CD8<sup>+</sup>, IFN-<italic toggle="yes">&#947;</italic>, T cell response specific for tumor-associated mitochondrial antigens</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B19-vaccines-04-00018" ref-type="bibr">19</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cytolytic T lymphocytes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mtDNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls the expression of maternally transmitted antigens</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hearing impairment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-vaccines-04-00018" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-04-00018" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pyruvate dehydrogenase complexes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increases CD8+ T cells for immune-pathogenesis of PBC.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary biliary cirrhosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-vaccines-04-00018" ref-type="bibr">25</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitochondrial permeability transition pore (MPTP)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Connects the B cell antigen receptor to the effector caspases of apoptotic cell death</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">acute cerebral ischemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-vaccines-04-00018" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer cell (MCF-7) and DCs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitochondrial matrix (MM)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generates the apoptotic cancer cells providing tumor antigens for immune response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-vaccines-04-00018" ref-type="bibr">21</xref>,<xref rid="B27-vaccines-04-00018" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4T1 cell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increases pro-inflammatory IL-2, IL-6, IL-12, TNF-<italic toggle="yes">&#945;</italic> cytokines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-vaccines-04-00018" ref-type="bibr">28</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">T cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bcl-xL/Bcl-2 proteins in outer mitochondrial membrane (OMM)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARM causes T cell death by inhibiting Bcl-xL and down regulating signal-regulated kinase phosphorylation for immune homeostasis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-vaccines-04-00018" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-oxo-dehydrogenase enzymes in inner mitochondria membrane (IMM)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Up regulates the expression of MHC class II, produces IL-2 cytokine in response to PDH-E2/BCKD-E2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary biliary cirrhosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-vaccines-04-00018" ref-type="bibr">30</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Electron transport chain (ETC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generates ROS for the nuclear factor of activated T cells (NFAT) and IL-2 induction</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-vaccines-04-00018" ref-type="bibr">31</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytolytic T lymphocytes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pyruvate dehydrogenase complexes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increases CD8+ T cells for immune-pathogenesis of PBC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary biliary cirrhosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-vaccines-04-00018" ref-type="bibr">25</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="vaccines-04-00018-t002" position="float" orientation="portrait"><object-id pub-id-type="pii">vaccines-04-00018-t002_Table 2</object-id><label>Table 2</label><caption><p>Polymeric NP based antigen delivery systems.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Polymer System</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Preparation/Diameter (nm)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Activity/Outcome</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Delivery route</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Comments</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Double emulsion method/320 nm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVA and MPLA dual loading PLGA NPs show enhanced mucosal immune response with higher IgA titers production than individually loaded NPs.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA approved delivery system, (OVA +MPLA) PLGA NPs were stable up to one month.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-vaccines-04-00018" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dialysis method/300&#8211;600 nm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 p24 PLA NPs show the best CTL results, antibody production, cytokine secretion (IL-2, 4, 6, 10, INF-<italic toggle="yes">&#947;</italic>) within the controls.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLA NPs were stable for months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-vaccines-04-00018" ref-type="bibr">51</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PGA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dialysis method/200 nm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The hemagglutinin (HA) loaded PGA-NPs show enhanced CTL activity and greater production of IFN-<italic toggle="yes">&#947;</italic>, IL-4, and IL-6 <italic toggle="yes">in vitro</italic>. NPs vaccination shows better defense to influenza virus infection <italic toggle="yes">in vivo</italic> than controls.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low cost, safe, relatively abundance, water-soluble, biodegradable</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-vaccines-04-00018" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PMMA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reflux-filtration methods</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 Tat Protein loaded PMMA NPs show efficient cellular uptake, well-patterned antigen release properties, and enhanced immune responses with greater proliferation index and cytokine level (INF-<italic toggle="yes">&#947;</italic>, IL-2) compared to Tat alone.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Core-shell NPs were prepared. Tat was protected from oxidation. No severe damage was observed for Tat PMMA NPs.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-vaccines-04-00018" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PPS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Emulsion-incubation/size was not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVA loaded PPS NPs with longer peptide showed greater cellular uptake, enhanced IFN-&#947; secretion, and T cell activation both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tail vein injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surfactant pluronic F127 was used to stabilize NPs, PPS NPs internalized into cell via miscellaneous pathways.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B54-vaccines-04-00018" ref-type="bibr">54</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLA-PLGA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Double Emulsion-solvent evaporation method/450&#8211;800 nm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBsAg co-polymeric NPs show increased immune responses with enhanced sIgA levels and greater production of cytokines (IL-2, IFN-<italic toggle="yes">&#947;</italic>) <italic toggle="yes">in vivo</italic>.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular injection via pulmonary route</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To deliver hepatitis B vaccine; Certain toxicity to pulmonary epithelium still exists. Limited for oral vaccine delivery </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-vaccines-04-00018" ref-type="bibr">55</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA-PEG-TPP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nano-precipitation method</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ZnPc loaded co-polymeric NPs showed greatly enhanced T cell activation with combination of photodynamic therapy.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Ex vivo</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Copolymer is of non-immunogenic and nontoxic, and designed for mitochondria targeting delivery.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-vaccines-04-00018" ref-type="bibr">21</xref>,<xref rid="B56-vaccines-04-00018" ref-type="bibr">56</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-PLA-PEG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Double emulsion &amp; solvent evaporation/215 nm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The co-polymeric NPs showed elevated immune response <italic toggle="yes">in vivo</italic>. Cytokine levels (IFN-<italic toggle="yes">&#947;</italic> and IL-2) were greatly enhanced.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The NPs was stable in gastric and intestinal fluids. 90% of hepatitis B antigen was encapsulated.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-vaccines-04-00018" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCL&#8211;PEG&#8211;PCL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Emulsion-solvent evaporation method/137 nm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The co-polymeric NPs delivery of bFGF antigen induces better antibody production for immune response <italic toggle="yes">in vivo</italic> than antigen alone.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A few studies have been made on this co-polymeric system.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B58-vaccines-04-00018" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ionotropic gelation technique/160&#8211;200 nm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rHBsAg loaded chitosan NPs induced pretty delay immune response but much greater production of IgG than conventional alum vaccines <italic toggle="yes">in vivo</italic>.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular or intranasal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NPs could be damaged by centrifugation-resuspension cycles. NPs could release antigen in a well-controlled pattern.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-vaccines-04-00018" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitoson-PLGA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Emulsification-solvent extraction/448 nm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitoson/PLGA NPs show gradual release of OVA up to 100% in 15 days, effective cellular uptake by crossing nasal epithelium, efficient T cell proliferation and stimulation <italic toggle="yes">in vivo</italic>.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nasal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NPs charge, size, and antige release properties are critical factors for vaccination.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B59-vaccines-04-00018" ref-type="bibr">59</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>PLA: poly(<sc>d</sc>,<sc>l</sc>-lactide); PCL: poly(&#949;-caprolactone); PGA: poly(<italic toggle="yes">&#947;</italic>-glutamic acid); PLGA: poly(lactic-co-glycolic acid); PEG: Polyethylene glycol; PCL: poly(<italic toggle="yes">&#603;</italic>-caprolactone); PPS: Poly(propylene sulfide); PMMA: poly(methylmethacrylate).</p></fn></table-wrap-foot></table-wrap><table-wrap id="vaccines-04-00018-t003" position="float" orientation="portrait"><object-id pub-id-type="pii">vaccines-04-00018-t003_Table 3</object-id><label>Table 3</label><caption><p>A summary of liposome-based antigen delivery systems.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Liposome Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Example</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Advantage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disadvantage</th></tr></thead><tbody><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Liposomal NP</td><td align="center" valign="middle" rowspan="1" colspan="1">E7 Peptide vaccinates against HPV [<xref rid="B14-vaccines-04-00018" ref-type="bibr">14</xref>]</td><td rowspan="3" align="center" valign="middle" colspan="1">No hypersensitivity reactions</td><td rowspan="3" align="center" valign="middle" colspan="1">Vulnerable to deoxyribonulease</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Plasmid DNA vaccinates against influenza [<xref rid="B77-vaccines-04-00018" ref-type="bibr">77</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HSP70 targets tumors [<xref rid="B78-vaccines-04-00018" ref-type="bibr">78</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">D. pteronyssinus vaccination againsts asthma [<xref rid="B79-vaccines-04-00018" ref-type="bibr">79</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Do not create antibodies against the phospholipid components</td><td align="center" valign="middle" rowspan="1" colspan="1">Do not target antigen-presenting cells well</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DNA-hsp65 vaccinates against tuberculosis [<xref rid="B80-vaccines-04-00018" ref-type="bibr">80</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Can release antigens over long period of time</td><td align="center" valign="middle" rowspan="1" colspan="1">Short systemic half life</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hepatitis A virus vaccinates against Hepatitis A [<xref rid="B81-vaccines-04-00018" ref-type="bibr">81</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Potential to cross epithelial barriers</td><td align="center" valign="middle" rowspan="1" colspan="1">Difficulty keeping certain molecules encapsulated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV type 1 vaccinates against AIDS [<xref rid="B82-vaccines-04-00018" ref-type="bibr">82</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low toxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Solid Lipid NP</td><td rowspan="2" align="center" valign="middle" colspan="1">Cystosine-guanine containing oligodeoxynucleotides (CpG ODN) antigen treats allergies and inflammatory disease [<xref rid="B83-vaccines-04-00018" ref-type="bibr">83</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Stimulate a more effective immune response due to a good pharmacokinetic profile</td><td align="center" valign="middle" rowspan="1" colspan="1">Poor stability and biodistribution</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Capable of reversible denaturation</td><td align="center" valign="middle" rowspan="1" colspan="1">Low loading capacity</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein antigen vaccinates against hepatitis B and malaria [<xref rid="B84-vaccines-04-00018" ref-type="bibr">84</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quick production time</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colloidal structures are present</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Liposome-polycation-DNA (LPD)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HPV 16 E7 protein used to vaccinate against cervical cancer and HPV [<xref rid="B85-vaccines-04-00018" ref-type="bibr">85</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Safe toxicity profile</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Most effective targeting is with proteins</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The plasmid DNA and cationic liposomes are immunostimulatory</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polymerized Liposomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cationic antimicrobial peptides (AMPs) vaccinates against Pseudomonas aeruginosa [<xref rid="B86-vaccines-04-00018" ref-type="bibr">86</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stable in the GI tract</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inconsistent targeting</td></tr></tbody></table></table-wrap><table-wrap id="vaccines-04-00018-t004" position="float" orientation="portrait"><object-id pub-id-type="pii">vaccines-04-00018-t004_Table 4</object-id><label>Table 4</label><caption><p>Summary of other NPs-based antigen delivery systems.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NPs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Example</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Advantage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disadvantage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Modified Diamond NPs</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mussel Adhesive Protein (MAP) antigen</td><td align="center" valign="middle" rowspan="1" colspan="1">Strong and specific antibody response</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Studies show that the NPs may adhere to the GI tract and block gut cells</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B87-vaccines-04-00018" ref-type="bibr">87</xref>,<xref rid="B88-vaccines-04-00018" ref-type="bibr">88</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NPs have efficient surface exposure</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gold NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T-helper ovalbumin<sub>323&#8211;339</sub> peptide (OVA<sub>323&#8211;339</sub>), CpG1668 oligodeoxynucleotide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Able to deliver fully synthetic carbohydrate-antigens, larger accumulation in a local lymph node</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">They are highly polarizable and are prone to aggregation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-vaccines-04-00018" ref-type="bibr">89</xref>,<xref rid="B90-vaccines-04-00018" ref-type="bibr">90</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Silver NP</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CD4 and gp120 for HIV and monkey pox</td><td align="center" valign="middle" rowspan="1" colspan="1">Exhibit antiviral tendencies</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Tests show that these NPs aggregate in the presence of cations</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B91-vaccines-04-00018" ref-type="bibr">91</xref>,<xref rid="B92-vaccines-04-00018" ref-type="bibr">92</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Has electrostatic double layer repulsion which stabilizes dispersion</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Aluminum Oxide NP</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HIV gp120 C4 antigen for HIV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Less inhibited by pinocytosis and phagocytosis once in the body</td><td align="center" valign="middle" rowspan="1" colspan="1">Tend to aggregate when the pH changes</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B93-vaccines-04-00018" ref-type="bibr">93</xref>,<xref rid="B94-vaccines-04-00018" ref-type="bibr">94</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surface charge is not particularly stable</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interbilayer-crosslinked multilamellar vesicles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VMP001- protein based malaria antigen for malaria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elicit a powerful T-cell response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rapid release when exposed to endolysosomal lipases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-vaccines-04-00018" ref-type="bibr">95</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Papaya Mosaic Virus Capsid Protein NP (PapMV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleoprotein Antigen for influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Very stable NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Only been used when working with influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B96-vaccines-04-00018" ref-type="bibr">96</xref>,<xref rid="B97-vaccines-04-00018" ref-type="bibr">97</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Single Walled Carbon Nanotubes</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prostate-Specific Antigen for prostate cancer</td><td align="center" valign="middle" rowspan="1" colspan="1">High affinity for graphite structures</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Poor survival times</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B98-vaccines-04-00018" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">High selectivity</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Active immune response</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silica NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bovine Serum Albumin for HIV, influenza, and Hepatitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chemically stable, good biocompatibility, low toxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ineffective for quick release</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B99-vaccines-04-00018" ref-type="bibr">99</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Calcium Phosphate Adjuvant</td><td align="center" valign="middle" rowspan="1" colspan="1">Mucosal delivery of herpes simplex virus type 2 antigen against the herpes virus</td><td rowspan="2" align="center" valign="middle" colspan="1">Very low toxicity</td><td rowspan="2" align="center" valign="middle" colspan="1">Tendency towards adverse reactions</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B100-vaccines-04-00018" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-04-00018" ref-type="bibr">101</xref>,<xref rid="B102-vaccines-04-00018" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Epstein-Barr virus proteins against Epstein-Barr virus</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Diphtheria Toxoid against Diphtheria</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">No detectable immunoglobulin E response</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Relatively small binding capacity</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetanus Toxoid against tetanus</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Aluminum Phosphate Adjuvant</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Hepatitis B surface antigen against Hepatitis B</td><td align="center" valign="middle" rowspan="1" colspan="1">Enhance antibody responses in DNA vaccines</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Thermal stability of the protein is reduced once absorbed</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B103-vaccines-04-00018" ref-type="bibr">103</xref>,<xref rid="B104-vaccines-04-00018" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proteins absorb well if oppositely charged</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Virus-like Particles</td><td rowspan="2" align="center" valign="middle" colspan="1">HPV-16/18 against human papilloma virus</td><td align="center" valign="middle" rowspan="1" colspan="1">Can be produced for mucosal delivery</td><td rowspan="2" align="center" valign="middle" colspan="1">Incapable of co-expression</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B105-vaccines-04-00018" ref-type="bibr">105</xref>,<xref rid="B106-vaccines-04-00018" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-04-00018" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cheap production</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B core antigen against Hepatitis B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLP size is favorable for being taken up by dendritic cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not readily taken up by cells other than DCs</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Lipopeptides</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Hepatitis B vaccine, Human immunodeficiency virus vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Highly immunogenic</td><td align="center" valign="middle" rowspan="1" colspan="1">Require organic solvents or detergents</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B108-vaccines-04-00018" ref-type="bibr">108</xref>,<xref rid="B109-vaccines-04-00018" ref-type="bibr">109</xref>,<xref rid="B110-vaccines-04-00018" ref-type="bibr">110</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Do not need ad adjuvant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poor stability over time</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Bacterial DNA</td><td align="center" valign="middle" rowspan="1" colspan="1">Ovalbumin antigen against tumor growth</td><td align="center" valign="middle" rowspan="1" colspan="1">Activate natural killer cells</td><td align="center" valign="middle" rowspan="1" colspan="1">Low immunogenicity</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B111-vaccines-04-00018" ref-type="bibr">111</xref>,<xref rid="B112-vaccines-04-00018" ref-type="bibr">112</xref>,<xref rid="B113-vaccines-04-00018" ref-type="bibr">113</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gp140 against human immunodeficiency virus</td><td align="center" valign="middle" rowspan="1" colspan="1">Cost efficient</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DNA is subject to degradation</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B core antigen against Hepatitis B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non toxic</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Lipopolysaccharide</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Brucella</italic> against brucellosis</td><td align="center" valign="middle" rowspan="1" colspan="1">Biodegradable</td><td align="center" valign="middle" rowspan="1" colspan="1">High toxicity</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B114-vaccines-04-00018" ref-type="bibr">114</xref>,<xref rid="B115-vaccines-04-00018" ref-type="bibr">115</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Allergy vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good binding</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High inflammatory response</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Layered double hydroxide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovalbumin against tumor, DNA against melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low toxic, biocompatible, controllable antigen release</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Toxic activity of LDHs still exists in <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-vaccines-04-00018" ref-type="bibr">75</xref>,<xref rid="B116-vaccines-04-00018" ref-type="bibr">116</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="vaccines-04-00018-t005" position="float" orientation="portrait"><object-id pub-id-type="pii">vaccines-04-00018-t005_Table 5</object-id><label>Table 5</label><caption><p>Summary of the lipophilic cations as mitochondria targeting moiety.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Targeting moiety</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Examples</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcome</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phospholipid (PL)-PEG-NH<sub>2</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single walled carbon nanotube functionalization (SWNT-PL-PEG)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To reduce nonspecific binding effect of SWNT surface. To improve the solubility of SWNTs in aqueous solutions. To accumulate in the mitochondria of normal and cancer cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B121-vaccines-04-00018" ref-type="bibr">121</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TPP<sup>+</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA-PEG-TPP as carrier for ZnPc</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To induce cytotoxicity in cancer cells under light irradiation, which is used to activate DCs </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-vaccines-04-00018" ref-type="bibr">21</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Rhodamine 123</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Liposomes-rhodamine-123-conjugated polymer</td><td align="center" valign="middle" rowspan="1" colspan="1">Least toxic among the liphophilic dye</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B118-vaccines-04-00018" ref-type="bibr">118</xref>,<xref rid="B122-vaccines-04-00018" ref-type="bibr">122</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Facilitate the cellular association and internalization, direct the trafficking of NPs to mitochondria, and substantial cell killing was observed as the drug cargo</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Methyltriphenyl phosphonium</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">Did not protect against cell death.</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B119-vaccines-04-00018" ref-type="bibr">119</xref>,<xref rid="B123-vaccines-04-00018" ref-type="bibr">123</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#916;<italic toggle="yes">&#968;</italic><sub>m</sub> was selectively depolarized</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Dequalinium (DQA)</td><td align="center" valign="middle" rowspan="1" colspan="1">DQA-PEG(5000)-DSPE</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">To cause cell death by inhibiting the mtDNA synthesis</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B124-vaccines-04-00018" ref-type="bibr">124</xref>,<xref rid="B125-vaccines-04-00018" ref-type="bibr">125</xref>,<xref rid="B126-vaccines-04-00018" ref-type="bibr">126</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DQA-PEG(2000)-DSPE)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MKT-007</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A mitochondria localized cationic dye, causes selective death of cancer cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B127-vaccines-04-00018" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">F16</td><td align="center" valign="middle" rowspan="1" colspan="1">F16 conjugated with 5-fluorouracil</td><td align="center" valign="middle" rowspan="1" colspan="1">F16 was used as a vehicle, selectively inhibits tumor cell proliferation and dissipates &#916;<italic toggle="yes">&#968;</italic><sub>m</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B128-vaccines-04-00018" ref-type="bibr">128</xref>,<xref rid="B129-vaccines-04-00018" ref-type="bibr">129</xref>]</td></tr><tr style="border-top:solid thin"><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">N</italic>-Heterocyclic Carbene (NHC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gold(I)-NHC Complex</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Au(I)-NHC complexes toxic to breast cancer cell (MDA-MB-231, MDA-MB-468), but not to normal cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B130-vaccines-04-00018" ref-type="bibr">130</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="vaccines-04-00018-t006" position="float" orientation="portrait"><object-id pub-id-type="pii">vaccines-04-00018-t006_Table 6</object-id><label>Table 6</label><caption><p>Summary of peptides with a mitochondria targeting sequence.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequence</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Targets</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Comments</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mitochondrial alanine aminotransferase (mALT)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">MSATRMQLLSPRNVRLLSRGRSELFAGGSGGGPRVRSLISPPLSSSSPGRALSSVSATRRGLPKEKMTENGVSSRAKVLTIDT</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Through interaction with translocases of the outer and inner mitochondrial membranes</td><td align="center" valign="middle" rowspan="1" colspan="1">Exhibits higher affinity for L-alanine</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B143-vaccines-04-00018" ref-type="bibr">143</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amino acids 1&#8211;83 contains MTS</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MTS-ExoIII-TAT-fusion protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLSRAVCGTSRQLAPALGYLGSRQ</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitochondrial matrix</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">More efficient in mtDNA damage and less repair to cancer cell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B144-vaccines-04-00018" ref-type="bibr">144</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AoPlaA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLSCTSPLLRGACHNMGAAKALRLRWTVPPAVLIALGSGALYTTSGQTLYYKNSVQQTD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitochondrial intermembrane space</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It is a cytosolic phospholipase A2 (cPLA2) like protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B145-vaccines-04-00018" ref-type="bibr">145</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p53 Protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLFNLRILLNNAAFRNGHNFMVRNFRCGQPLQ</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Localizes within the membrane compartment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitochondrial accumulation of p53 is rapid, and precedes the apoptotic cascade.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B146-vaccines-04-00018" ref-type="bibr">146</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SS peptide</td><td align="center" valign="middle" rowspan="1" colspan="1">2&#8217;,6&#8217;-dimethyltyrosine-D-Arg-Phe-Lys-NH<sub>2</sub></td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inner mitochondrial membrane</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prevents mitochondrial depolarization</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B147-vaccines-04-00018" ref-type="bibr">147</xref>,<xref rid="B148-vaccines-04-00018" ref-type="bibr">148</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Phe-D-Arg-Phe-Lys-NH2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">d-Arg-2&#8217;,6&#8217;-dimethyltyrosine-Lys-Phe-NH<sub>2</sub></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XJB-5-131</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4-hydroxy-2,2,6,6-tetramethyl piperidine-1-oxyl conjugated to nitroxide-Leu-D-Phe-Pro-Val-Orn</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitochondrial membrane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ROS/RNS scavenger</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B149-vaccines-04-00018" ref-type="bibr">149</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gramicidin S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Boc-Leu-<sup>D</sup>Phe-Val-Orn(Cbz)-OMe</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitochondrial membrane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Electron scavenger</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B150-vaccines-04-00018" ref-type="bibr">150</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nitroxide/Hemigramicidin S Conjugate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemigramicidin S-4-amino-2,2,6,6-tetramethyl-piperidine-N-oxyl (hemi-GS-TEMPO) 5-125</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Accumulates at the interface of mitochondrial membrane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acts as electron scavenger and provides the radioprotection of gamma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B151-vaccines-04-00018" ref-type="bibr">151</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COX1<sub>291&#8211;306</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MFTVGLDVDTRTYFT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mtDNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stimulates the CD8<sup>+</sup> IFN-<italic toggle="yes">&#947;</italic><sup>+</sup> T cell response specific for tumor-associated mitochondrial Ags</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B19-vaccines-04-00018" ref-type="bibr">19</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytochrome P450 2E1 (P450 MT5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MAVLGITVALLGWMVILLFI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitochondrial out and inner membrane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reacts with cytochrome P450 in mitochondria </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B152-vaccines-04-00018" ref-type="bibr">152</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activating transcription factor associated with stress-1 (ATFS-1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAVAYREAARAE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inner mitochondrial membrane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATFS-1 is degraded in mitochondria, which helps to maintain the mitochondrial homeostasis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B153-vaccines-04-00018" ref-type="bibr">153</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLA peptide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><sub>D</sub>(KLAKLAK)<sub>2</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitochondrial membrane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLA lysine units interact with the membranes for mitochondria uptake via hydrogen bonding and electrostatic attraction</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B154-vaccines-04-00018" ref-type="bibr">154</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RLA peptide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><sub>D</sub>[RLARLAR]<sub>2</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitochondrial outer membrane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The substitution of D-lysines in KLA with D-arginines improves the plasma membrane permeability and increases mitochondrial accumulation of RLA (as early as 6 min)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B155-vaccines-04-00018" ref-type="bibr">155</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRWQEMGYIFYPRKLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mtDNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16-amino-acid peptide, which promotes metabolic homeostasis and prevents the obesity and insulin resistance </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-vaccines-04-00018" ref-type="bibr">156</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Y- or M-conjugate</td><td align="center" valign="middle" rowspan="1" colspan="1">NH<sub>2</sub>-MLSLRQSIRFFKPAT-o-o-N-TTCCTCGCTCACT-c (Y conjugate)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Matrix</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Accesses into the matrix through outer and inner mitochondria protein import channels </td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B157-vaccines-04-00018" ref-type="bibr">157</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NH-MALLRGVFIVAAKRTPF-o-o-<sub>N-</sub>GATTCTTCACCGT<sub>-C</sub> (M-conjugate)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitochondria-penetrating peptides (MPPs)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F<sub>X-</sub>r-F<sub>X-</sub>K<sub>-</sub>F<sub>X-</sub>r<sub>-</sub>F<sub>X-</sub>K, F-r-F-K-F-r-F-K, F-r-F<sub>X</sub>-K-F-r-F<sub>X</sub>-K, F-r-Y-K-F-r-Y-K, F<sub>X</sub>-r-F<sub>X</sub>-K,F-r-F-K, F-r-F<sub>X</sub>-K, F-r-F<sub>2</sub>-K, F-r-Nap-K, F-r-Hex-K, F-r-Y<sub>Me</sub>-K, F-r-F<sub>F</sub>-K, F-r-Y-K, Y-r-Y-K</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Matrix</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systematic series of MPPs were studied, delivery of nonpolar species into mitochondria has been demonstrated to be successful</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B158-vaccines-04-00018" ref-type="bibr">158</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MTS-Cys peptide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NH<sub>2</sub>-MVSGSSGLAAARLLSRTFLLQQNGIRHGSYC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitochondrial outer membrane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MTS peptide can be enhanced slightly outer stearyl-R8 modification</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B159-vaccines-04-00018" ref-type="bibr">159</xref>,<xref rid="B160-vaccines-04-00018" ref-type="bibr">160</xref>]</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>